PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32146032-0 2020 Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 83-87 32173232-0 2020 Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 137-141 32102624-1 2021 Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 17-21 32102624-1 2021 Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 89-93 32102624-2 2021 However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 9-13 31486987-1 2020 Osimertinib is a key drug for cancer patients with EGFR mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 51-55 32209253-0 2020 Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 72-76 32193290-0 2020 Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 77-81 32193290-1 2020 Osimertinib, a mutant-specific third generation EGFR TKI, is emerging as the preferred first-line therapy for EGFR mutant lung cancer, yet resistance inevitably develops in patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 48-52 32154925-4 2020 METHODS: Advanced EGFR-mutant NSCLC patients treated with olmutinib or osimertinib who underwent a rebiopsy before treatment or after progression were analyzed retrospectively. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 18-22 32154925-7 2020 Of the 36 patients with posttreatment biopsies, EGFR-dependent mechanisms, including C797S and L718Q mutations, were observed in 10 (28%) patients: 29% (5/17) in the osimertinib group and 26% (5/19) in the olmutinib group. osimertinib 166-177 epidermal growth factor receptor Homo sapiens 48-52 32154925-8 2020 EGFR-independent mechanisms were detected in 21 patients (21/36, 58%): 65% (11/17) in the osimertinib group and 53% (10/19) in the olmutinib group. osimertinib 90-101 epidermal growth factor receptor Homo sapiens 0-4 32154925-9 2020 The disappearance of EGFR T790M was detected in 14 patients (39%); of these patients, 59% (10/17) were treated with osimertinib and 21% (4/19) were treated with olmutinib. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 21-25 32154925-11 2020 CONCLUSION: Resistance acquired after third-generation EGFR TKIs is associated with diverse pathways; however, treatment with osimertinib is primarily associated with a loss of EGFR T790M and the subsequent emergence of EGFR-independent resistance mechanisms. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 55-59 32154925-11 2020 CONCLUSION: Resistance acquired after third-generation EGFR TKIs is associated with diverse pathways; however, treatment with osimertinib is primarily associated with a loss of EGFR T790M and the subsequent emergence of EGFR-independent resistance mechanisms. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 177-181 32154925-11 2020 CONCLUSION: Resistance acquired after third-generation EGFR TKIs is associated with diverse pathways; however, treatment with osimertinib is primarily associated with a loss of EGFR T790M and the subsequent emergence of EGFR-independent resistance mechanisms. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 177-181 32217611-0 2020 Resistance to First-Line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 40-44 32217611-1 2020 Matched pre-/post-treatment tissue biopsies from EGFR-mutant NSCLC patients demonstrate that histologic transformations, including both SCLC and squamous transformation, are unexpectedly common among patients progressing on first-line osimertinib. osimertinib 235-246 epidermal growth factor receptor Homo sapiens 49-53 32200138-0 2020 Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 58-62 32200138-1 2020 OBJECTIVES: In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. osimertinib 118-129 epidermal growth factor receptor Homo sapiens 107-111 32213382-0 2020 Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 80-84 32213382-7 2020 This study focused on EGFR mutations in ctDNA of 82 systemically pre-treated patients receiving osimertinib. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 22-26 32213382-8 2020 RESULTS: Clearing all EGFR mutations from the blood after osimertinib treatment, significantly predicted progression-free survival, objective response rates and disease control rates. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 22-26 32213382-13 2020 CONCLUSION: The clearing of EGFR mutations in ctDNA after osimertinib treatment initiation in patients with advanced NSCLC is useful as a positive predictor of clinical outcome. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 28-32 32139298-0 2020 TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 108-112 32139298-1 2020 BACKGROUND: Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 54-86 32139298-1 2020 BACKGROUND: Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 88-92 32145595-1 2020 OBJECTIVES: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 93-125 32234920-0 2020 Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 83-115 32234920-5 2020 The overall response rate to EGFR-TKI treatment following osimertinib tended to be lower than that for cytotoxic agents (0% vs. 44.4%). osimertinib 58-69 epidermal growth factor receptor Homo sapiens 29-33 31006308-1 2020 Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 64-96 32216945-0 2020 Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib. osimertinib 122-133 epidermal growth factor receptor Homo sapiens 67-71 32145595-1 2020 OBJECTIVES: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 127-131 32145595-1 2020 OBJECTIVES: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 210-214 32093857-0 2020 Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 13-17 32231715-0 2020 The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. osimertinib 82-93 epidermal growth factor receptor Homo sapiens 18-22 32231715-1 2020 Background and Purpose: Pervious studies have demonstrated that the loss of EGFR T790M after Osimertinib treatment may be the cause of Osimertinib resistance. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 76-80 32231715-1 2020 Background and Purpose: Pervious studies have demonstrated that the loss of EGFR T790M after Osimertinib treatment may be the cause of Osimertinib resistance. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 76-80 32231715-9 2020 Conclusions: Our findings confirm the persistence of T790M is associated with the clinical benefits of Osimertinib in NSCLC patients with baseline EGFR T790M mutation treated with Osimertinib. osimertinib 103-114 epidermal growth factor receptor Homo sapiens 147-151 32211870-4 2020 Osimertinib mesylate is a mutant epidermal growth factor receptor (EGFR) inhibitor that can penetrate the blood-brain barrier and inhibit tumor cell survival and proliferation in patients with non-small cell lung cancer (NSCLC) with specific EGFR alterations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 33-65 32211870-4 2020 Osimertinib mesylate is a mutant epidermal growth factor receptor (EGFR) inhibitor that can penetrate the blood-brain barrier and inhibit tumor cell survival and proliferation in patients with non-small cell lung cancer (NSCLC) with specific EGFR alterations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 67-71 32211870-4 2020 Osimertinib mesylate is a mutant epidermal growth factor receptor (EGFR) inhibitor that can penetrate the blood-brain barrier and inhibit tumor cell survival and proliferation in patients with non-small cell lung cancer (NSCLC) with specific EGFR alterations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 242-246 32211870-18 2020 Conclusions and Relevance: Findings reported herein support a potential role for osimertinib in the treatment of patients with metastatic EGFR-variant NSCLC and IMD treated with osimertinib. osimertinib 81-92 epidermal growth factor receptor Homo sapiens 138-142 32129931-0 2020 Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 32-36 32129931-1 2020 BACKGROUND: Osimertinib is recommended for T790M mutation-positive advanced non-small cell lung cancer (NSCLC) resistant to first- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 153-185 32129931-1 2020 BACKGROUND: Osimertinib is recommended for T790M mutation-positive advanced non-small cell lung cancer (NSCLC) resistant to first- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 187-191 32129931-15 2020 KEY POINTS: Significant findings of the study Osimertinib shows efficacy even as later-line treatment in T790M mutation-positive NSCLC patients previously treated with EGFR-TKIs. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 168-172 32129931-17 2020 What this study adds Osimertinib was approved for previously EGFR-TKI-treated EGFR T790M-positive NSCLC. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 61-65 32129931-17 2020 What this study adds Osimertinib was approved for previously EGFR-TKI-treated EGFR T790M-positive NSCLC. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 78-82 32129931-18 2020 With the increasing frequency of its use as first-line treatment, this study provides valuable evidence for the efficacy and safety of osimertinib for previously EGFR-TKI-treated NSCLC. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 162-166 32224854-8 2020 Our clinical data in T790M carriers strongly support the clinical benefits of osimertinib treatment guided by both EGFR mutation tests. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 115-119 32093862-0 2020 Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 58-62 31447233-0 2019 Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]. osimertinib 204-215 epidermal growth factor receptor Homo sapiens 53-57 31581843-1 2020 Objective: ASTRIS is a large real-world, open-label, multinational clinical study of osimertinib in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive advanced non-small cell lung cancer (NSCLC) who have previously received a tyrosine kinase inhibitor (TKI). osimertinib 85-96 epidermal growth factor receptor Homo sapiens 114-146 31581843-1 2020 Objective: ASTRIS is a large real-world, open-label, multinational clinical study of osimertinib in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive advanced non-small cell lung cancer (NSCLC) who have previously received a tyrosine kinase inhibitor (TKI). osimertinib 85-96 epidermal growth factor receptor Homo sapiens 148-152 31183631-0 2020 Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 104-108 31183631-1 2020 3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non-small-cell lung cancers (NSCLC) with EGFR mutations. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 76-80 31183631-1 2020 3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non-small-cell lung cancers (NSCLC) with EGFR mutations. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 180-184 31183631-5 2020 In particular, we assessed the efficacy of osimertinib for NSCLC with EGFR T790 M mutations in patients who were diagnosed with EGFR T790 M mutation by malignant effusion. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 70-74 31183631-5 2020 In particular, we assessed the efficacy of osimertinib for NSCLC with EGFR T790 M mutations in patients who were diagnosed with EGFR T790 M mutation by malignant effusion. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 128-132 31183631-6 2020 Among 90 patients with EGFR T790 M mutation who started osimertinib treatment after EGFR-TKI failure, 21 were diagnosed from malignant effusions excluding cerebrospinal fluid (F group) and 69 using other methods including tissue biopsies (NF group). osimertinib 56-67 epidermal growth factor receptor Homo sapiens 23-27 31183631-6 2020 Among 90 patients with EGFR T790 M mutation who started osimertinib treatment after EGFR-TKI failure, 21 were diagnosed from malignant effusions excluding cerebrospinal fluid (F group) and 69 using other methods including tissue biopsies (NF group). osimertinib 56-67 epidermal growth factor receptor Homo sapiens 84-88 31183631-11 2020 The present study showed that the efficacy of osimertinib for NSCLC in which EGFR T790 M mutation is detected by malignant effusion may be less than in EGFR T790 M-mutated NSCLC detected by other methods. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 77-81 31648999-0 2020 Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. osimertinib 165-176 epidermal growth factor receptor Homo sapiens 106-110 31648999-1 2020 BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 102-134 31648999-1 2020 BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 136-140 32127933-1 2020 Background: It is still controversial to employ osimertinib as the first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients in practice. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 90-94 32127933-10 2020 Conclusions: Patients developing acquired T790M mutation during EGFR-TKI treatment had a better OS of osimertinib treatment. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 64-68 31345012-1 2020 Purpose: Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 63-95 31345012-1 2020 Purpose: Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 97-101 31345012-1 2020 Purpose: Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 179-183 31345012-1 2020 Purpose: Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 179-183 31447233-0 2019 Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]. osimertinib 204-215 epidermal growth factor receptor Homo sapiens 153-157 32010586-0 2019 Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study). osimertinib 44-55 epidermal growth factor receptor Homo sapiens 106-138 32010586-1 2019 Background: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has a potent inhibitory effect against both T790M resistance mutations and EGFR-TKI sensitizing in EGFR, with a relatively low affinity for wild-type EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 104-108 32010586-1 2019 Background: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has a potent inhibitory effect against both T790M resistance mutations and EGFR-TKI sensitizing in EGFR, with a relatively low affinity for wild-type EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 190-194 32010586-4 2019 Osimertinib has been reported to provide survival benefits to EGFR mutation-positive patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 62-66 32010586-11 2019 Discussion: We are conducting an intervention study to investigate the safety and efficacy of osimertinib as a first-line treatment agent for EGFR mutation-positive NSCLC in patients aged >=75 years. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 142-146 31802944-1 2019 Purpose: Osimertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted for both EGFR sensitizing mutations and T790M resistance mutation in patients with non-small-cell lung cancer (NSCLC). osimertinib 9-20 epidermal growth factor receptor Homo sapiens 46-78 31445213-1 2019 Before initiating treatment of advanced non-small-cell lung cancer with tyrosine kinase inhibitors (eg, erlotinib, gefitinib, osimertinib, afatinib), which inhibit the catalytic activity of epidermal growth factor receptor (EGFR), clinical guidelines require determining the EGFR mutational status for activating (EGFR exons 18, 19, 20, or 21) and resistance mutations (EGFR exon 20). osimertinib 126-137 epidermal growth factor receptor Homo sapiens 190-222 31377341-0 2019 EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 0-4 31377341-0 2019 EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 59-63 31377341-0 2019 EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 59-63 31377341-0 2019 EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 59-63 31377341-1 2019 INTRODUCTION: Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation EGFR inhibitor are evolving. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 51-55 31377341-2 2019 Whether durable control of subsequently osimertinib-resistant NSCLC with the EGFR-sensitizing mutation (SM)/C797S is possible with first-generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resultant acquired resistance profile. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 77-81 31439584-1 2019 PURPOSE: To assess the utility of the cobas EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with EGFR-mutated (EGFRm) (Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125). osimertinib 105-116 epidermal growth factor receptor Homo sapiens 46-50 31439584-1 2019 PURPOSE: To assess the utility of the cobas EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with EGFR-mutated (EGFRm) (Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125). osimertinib 105-116 epidermal growth factor receptor Homo sapiens 143-147 31793439-4 2019 This review summarizes the clinical efficacy and tolerability of EGFR-TKIs, including osimertinib, in EGFR-mutated advanced NSCLC. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 102-106 31793439-7 2019 Osimertinib, a potent third-generation TKI, irreversibly inhibits mutated EGFR alleles, including T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 74-78 31793439-9 2019 Based on the efficacy and safety results, recently the National Comprehensive Cancer Network (NCCN) has included osimertinib as the "preferred first-line of treatment" in patients with metastatic EGFR mutationpositive NSCLC. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 196-200 31802944-1 2019 Purpose: Osimertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted for both EGFR sensitizing mutations and T790M resistance mutation in patients with non-small-cell lung cancer (NSCLC). osimertinib 9-20 epidermal growth factor receptor Homo sapiens 80-84 31802944-1 2019 Purpose: Osimertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted for both EGFR sensitizing mutations and T790M resistance mutation in patients with non-small-cell lung cancer (NSCLC). osimertinib 9-20 epidermal growth factor receptor Homo sapiens 136-140 31802944-11 2019 Conclusion: Osimertinib was highly active in patients with pretreated advanced NSCLC who harbored EGFR T790M mutation, with manageable side-effects. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 98-102 31228625-9 2019 However, cells with osimertinib-induced resistance also showed EGFR translocation and lower phospho-EGF receptor but did not show Hippo pathway inhibition. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 63-67 31377341-4 2019 In addition, we retrospectively probed a case of EGFR SM lung adenocarcinoma treated with first-line osimertinib, followed by second-line erlotinib in the setting of EGFR SM/C797S. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 49-53 31377341-6 2019 A patient with EGFR delE746_T751insV NSCLC was treated with osimertinib with sustained response for 10 months before acquiring EGFR C797S. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 15-19 31377341-6 2019 A patient with EGFR delE746_T751insV NSCLC was treated with osimertinib with sustained response for 10 months before acquiring EGFR C797S. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 127-131 31377341-9 2019 CONCLUSION: EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 12-16 31377341-9 2019 CONCLUSION: EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 91-95 31432603-7 2019 Two out of three PDXs with AD histology had EGFR mutations (L858R or exon19 deletion) and were sensitive to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and osimertinib. osimertinib 175-186 epidermal growth factor receptor Homo sapiens 108-112 31432603-8 2019 Furthermore, in one of the two PDXs with an EGFR mutation, osimertinib resistance was induced that was associated with epithelial-to-mesenchymal transition. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 44-48 31393074-1 2019 Osimertinib is designed to target the secondary resistant EGFR T790M mutant and has shown outstanding clinical efficacy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 58-62 31228625-12 2019 Membrane/plasma translocation of EGFR induced by osimertinib may be another resistance phenomenon besides MNNG HOS transforming gene (c-MET) amplification, C797S mutation, and ERK pathway inhibition. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 33-37 31301315-0 2019 Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 79-83 31301315-1 2019 Although osimertinib, an EGFR tyrosine kinase inhibitor, has become the standard therapy for treating non-small cell lung cancer (NSCLC) patients with EGFR-activating mutation, upregulation of MCL-1 induces acquired resistance to osimertinib. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 25-29 31301315-1 2019 Although osimertinib, an EGFR tyrosine kinase inhibitor, has become the standard therapy for treating non-small cell lung cancer (NSCLC) patients with EGFR-activating mutation, upregulation of MCL-1 induces acquired resistance to osimertinib. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 151-155 31301315-6 2019 Mechanistically, MEK/ERK-dependent MCL-1 phosphorylation and Ku70-mediated MCL-1 overexpression confer osimertinib resistance in EGFR-mutant NSCLC cells. osimertinib 103-114 epidermal growth factor receptor Homo sapiens 129-133 31339357-0 2019 ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 75-79 30864019-2 2019 We aimed to explore the clinical impact of osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), on CNS metastases in patients with advanced NSCLC in real-world setting. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 135-139 30864019-3 2019 METHODS: Patients with advanced NSCLC who received osimertinib after progression of early-generation EGFR-TKIs and CNS metastases on baseline brain scan were retrospectively collected. osimertinib 51-62 epidermal growth factor receptor Homo sapiens 101-105 31265163-3 2019 A large global Phase III study (AURA3) demonstrated that osimertinib significantly prolonged progression-free survival (PFS) over platinum-doublet chemotherapy in patients with T790M-positive NSCLC who had progressed on previous EGFR-TKI therapy. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 229-233 31339357-1 2019 Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. osimertinib 5-16 epidermal growth factor receptor Homo sapiens 59-63 31445736-0 2019 A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 15-19 31298572-6 2019 Both osimertinib and dacomitinib should be considered as standard first-line treatment options for patients diagnosed with advanced EGFR-positive non-small-cell lung cancer. osimertinib 5-16 epidermal growth factor receptor Homo sapiens 132-136 31496745-2 2019 Three generations of EGFR TKIs are now approved for use in EGFR mutation-positive non-small cell lung cancer (NSCLC); the first-generation agents erlotinib, gefitinib, and icotinib; the second-generation ErbB family blockers afatinib and dacomitinib; and most recently, osimertinib, a third-generation EGFR TKI. osimertinib 270-281 epidermal growth factor receptor Homo sapiens 21-25 31501372-0 2019 [Osimertinib Was Effective for Liver Metastasis after Surgery for Lung Cancer with Simultaneous Expression of EGFR L858Ra nd T790M Mutations-A Case Report]. osimertinib 1-12 epidermal growth factor receptor Homo sapiens 110-114 31501372-6 2019 Thus, osimertinib was effective for liver metastasis of lung cancer with EGFR mutations of L858R and T790M. osimertinib 6-17 epidermal growth factor receptor Homo sapiens 73-77 30916819-0 2019 Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S. osimertinib 55-66 epidermal growth factor receptor Homo sapiens 111-115 30916819-7 2019 Although research has shown that Osimertinib is an effective treatment for EGFR L844V cells, this has not been shown for cells that have the C797S mutation. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 75-79 30916819-9 2019 METHODS: In the present study, we used the GROMACS software for molecular dynamics simulation to identify interactions between Osimertinib and the kinase part of EGFR in L844V and C797S mutants. osimertinib 127-138 epidermal growth factor receptor Homo sapiens 162-166 30916819-11 2019 Osimertinib was effective for the EGFR L844V mutation, but not for EGFR C797S. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 30875094-0 2019 Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 85-89 30875094-1 2019 Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 87-119 30875094-1 2019 Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 121-125 30875094-1 2019 Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 185-189 30875094-1 2019 Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 185-189 31478399-0 2019 Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 48-52 31478399-1 2019 Aim: Osimertinib improves progression-free survival in first-line EGFR mutation-positive non-small-cell lung cancer. osimertinib 5-16 epidermal growth factor receptor Homo sapiens 66-70 31393415-0 2019 A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment? osimertinib 103-114 epidermal growth factor receptor Homo sapiens 81-85 31316771-7 2019 The patient received treatment with the third-generation EGFR-TKI osimertinib, achieving a good clinical response. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 57-61 31262922-7 2019 We analyzed clinical data from NSCLC patients receiving osimertinib after progression following 1st- or 2nd-G EGFR-TKIs between March 28, 2016 and March 31, 2018. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 110-114 31262922-15 2019 Afatinib followed by osimertinib may be a therapeutic option for NSCLC harboring EGFR mutation. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 81-85 30613959-0 2019 Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 47-51 30613959-1 2019 Osimertinib is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 79-111 30613959-1 2019 Osimertinib is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 113-117 31235042-0 2019 Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 66-70 31463088-0 2019 Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 51-83 31290421-1 2019 Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 42-74 31290421-1 2019 Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 76-80 31290421-1 2019 Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 212-216 31289574-1 2019 Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 62-94 31289574-1 2019 Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 96-100 31289574-1 2019 Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 234-238 31261881-0 2019 Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. osimertinib 53-64 epidermal growth factor receptor Homo sapiens 80-84 31261881-1 2019 Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). osimertinib 198-209 epidermal growth factor receptor Homo sapiens 58-90 31261881-1 2019 Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). osimertinib 198-209 epidermal growth factor receptor Homo sapiens 92-96 31261881-1 2019 Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). osimertinib 198-209 epidermal growth factor receptor Homo sapiens 183-187 31346515-2 2019 The third-generation of EGFR-TKI Osimertinib is suitable for patients with EGFR mutation and T790M mutation. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 24-28 31346515-2 2019 The third-generation of EGFR-TKI Osimertinib is suitable for patients with EGFR mutation and T790M mutation. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 75-79 31301016-0 2019 Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 9-13 31301016-1 2019 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has demonstrated significant clinical benefit in EGFR T790M-mutated non-small-cell lung cancer (NSCLC) patients, with extensive research focusing on the mechanisms of acquired resistance. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 33-65 31301016-1 2019 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has demonstrated significant clinical benefit in EGFR T790M-mutated non-small-cell lung cancer (NSCLC) patients, with extensive research focusing on the mechanisms of acquired resistance. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 67-71 31301016-1 2019 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has demonstrated significant clinical benefit in EGFR T790M-mutated non-small-cell lung cancer (NSCLC) patients, with extensive research focusing on the mechanisms of acquired resistance. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 166-170 31301016-9 2019 Upon disease progression, an acquired L718V mutation within the EGFR kinase domain was found, which may interfere with the binding of osimertinib to the kinase domain and confer resistance regardless of T790M status. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 64-68 31301016-10 2019 CONCLUSIONS: This is the first clinical evidence of EGFR L718V giving rise to osimertinib resistance in a T790M-negative context, which provides valuable information for the discovery of resistance mechanisms to osimertinib and guidance for personalized NSCLC treatment in such patients. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 52-56 31301016-10 2019 CONCLUSIONS: This is the first clinical evidence of EGFR L718V giving rise to osimertinib resistance in a T790M-negative context, which provides valuable information for the discovery of resistance mechanisms to osimertinib and guidance for personalized NSCLC treatment in such patients. osimertinib 212-223 epidermal growth factor receptor Homo sapiens 52-56 31346928-0 2019 Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 6-10 31346928-0 2019 Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 28-32 31346928-8 2019 We found all patients in ARC2 having the highest ratio of AFT790M to AFmEGFR to have previously been treated with a 1G EGFR TKI and to show the longest osimertinib PFS compared to ARC3 (NR vs. 11.9 months, p = 0.060) and ARC1 (NR vs. 12.4 month, p = 0.045). osimertinib 152-163 epidermal growth factor receptor Homo sapiens 72-76 31346928-9 2019 CONCLUSIONS: Acquired T790M fraction of EGFR-mutated NSCLC is linked to different generations of prior EGFR TKI use and the later efficacy of osimertinib. osimertinib 142-153 epidermal growth factor receptor Homo sapiens 40-44 31346928-9 2019 CONCLUSIONS: Acquired T790M fraction of EGFR-mutated NSCLC is linked to different generations of prior EGFR TKI use and the later efficacy of osimertinib. osimertinib 142-153 epidermal growth factor receptor Homo sapiens 103-107 31315676-3 2019 This study aimed to report a case baring acquired EGFR L858R/L718Q mutation in the central nervous system induced by osimertinib, which was successfully overcome using afatinib. osimertinib 117-128 epidermal growth factor receptor Homo sapiens 50-54 31315676-7 2019 After 8 months, she experienced disease progression with leptomeningeal metastasis and switched to osimertinib based on an acquired EGFR T790 M mutation. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 132-136 31315676-11 2019 CONCLUSION: The acquired EGFR L718Q mutation in the cerebrospinal fluid resulted in subsequent resistance to osimertinib and could be partly overcome using afatinib, indicating a promising treatment option in the clinic. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 25-29 31380273-7 2019 Osimertinib was given to 17 of 20 patients with EGFR T790M mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 48-52 31371992-0 2019 Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 142-146 31372039-8 2019 Interestingly, RET fusion occurred only after osimertinib treatment, and contributed to drug resistance in 50% (6 of 12) of patients treated with osimertinib, indicating that fusions had different prevalence when functioning as resistance mechanisms to EGFR TKIs. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 253-257 30941723-6 2019 The third-generation EGFR-TKI osimertinib, initially approved as the second-line treatment for patients with T790-mutant NSCLC, demonstrated survival benefits in TKI-naive EGFR-mutated patients, especially in patients with CNS metastasis. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 21-25 30941723-6 2019 The third-generation EGFR-TKI osimertinib, initially approved as the second-line treatment for patients with T790-mutant NSCLC, demonstrated survival benefits in TKI-naive EGFR-mutated patients, especially in patients with CNS metastasis. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 172-176 30941723-8 2019 These data favor osimertinib in the first-line setting for EGFR-mutated NSCLC. osimertinib 17-28 epidermal growth factor receptor Homo sapiens 59-63 30930332-1 2019 Patients with EGFR-mutant non-small cell lung cancer who develop MET-driven resistance to an EGFR inhibitor-be it a first-, second-, or third-generation drug-stand to benefit from follow-up treatment with a combination of EGFR-targeted osimertinib and MET-blocking savolitinib, according to an interim analysis of two expansion cohorts from the multiarm TATTON trial. osimertinib 236-247 epidermal growth factor receptor Homo sapiens 14-18 31284441-0 2019 Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 123-127 31284441-7 2019 Here, we examined its chemosensitization effects on osimertinib, a third-generation EGFR-TKI with an excellent safety profile, in glioma stem cells (GSCs), which are CSCs of glioblastoma. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 84-88 30796031-0 2019 On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 45-49 30796031-0 2019 On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 139-143 30796031-1 2019 PURPOSE: The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 30-34 30796031-1 2019 PURPOSE: The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 172-176 30713295-0 2019 Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 93-125 30713295-0 2019 Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 127-131 30713295-1 2019 We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 132-164 30713295-1 2019 We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 166-170 30713295-6 2019 A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 115-119 31280508-0 2019 Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 78-110 30930332-1 2019 Patients with EGFR-mutant non-small cell lung cancer who develop MET-driven resistance to an EGFR inhibitor-be it a first-, second-, or third-generation drug-stand to benefit from follow-up treatment with a combination of EGFR-targeted osimertinib and MET-blocking savolitinib, according to an interim analysis of two expansion cohorts from the multiarm TATTON trial. osimertinib 236-247 epidermal growth factor receptor Homo sapiens 93-97 30930332-1 2019 Patients with EGFR-mutant non-small cell lung cancer who develop MET-driven resistance to an EGFR inhibitor-be it a first-, second-, or third-generation drug-stand to benefit from follow-up treatment with a combination of EGFR-targeted osimertinib and MET-blocking savolitinib, according to an interim analysis of two expansion cohorts from the multiarm TATTON trial. osimertinib 236-247 epidermal growth factor receptor Homo sapiens 93-97 31372272-0 2019 Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 153-185 31372272-1 2019 Background: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 141-173 31372272-1 2019 Background: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 175-179 30809659-1 2019 BACKGROUND: Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 44-76 30809659-1 2019 BACKGROUND: Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 78-82 30809659-1 2019 BACKGROUND: Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 135-139 30809659-1 2019 BACKGROUND: Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 135-139 30126856-0 2019 Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-20 30126856-1 2019 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor, initially approved for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) with T790M acquired resistance, and now approved in the first-line setting. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 98-130 30126856-1 2019 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor, initially approved for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) with T790M acquired resistance, and now approved in the first-line setting. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 132-136 30126856-14 2019 To minimize the risks of radiation-related toxicity, delaying radiation could be considered for some patients with EGFR-mutant NSCLC with brain metastases who initially respond to osimertinib in the second-line setting. osimertinib 180-191 epidermal growth factor receptor Homo sapiens 115-119 30126856-15 2019 IMPLICATIONS FOR PRACTICE: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recently approved for the first-line treatment of EGFR-mutant non-small cell lung cancer. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 61-93 30126856-15 2019 IMPLICATIONS FOR PRACTICE: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recently approved for the first-line treatment of EGFR-mutant non-small cell lung cancer. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 95-99 30126856-15 2019 IMPLICATIONS FOR PRACTICE: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recently approved for the first-line treatment of EGFR-mutant non-small cell lung cancer. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 177-181 31119481-12 2019 CONCLUSION: The efficacy of osimertinib as second-line treatment or more in octogenarian pretreated patients with EGFR T790M-mutated advanced NSCLC in a real-life setting was similar to that in randomized controlled trials. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 114-118 31138260-0 2019 Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 17-21 31138260-0 2019 Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 123-127 31138260-1 2019 BACKGROUND: The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 33-65 31138260-1 2019 BACKGROUND: The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 67-71 31138260-1 2019 BACKGROUND: The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 245-249 31138260-3 2019 In this study we investigated the combination of osimertinib with pemetrexed or cisplatin in EGFR-mutated NSCLC cell lines and xenografts. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 93-97 31138260-13 2019 CONCLUSIONS: Our results identify a combination between osimertinib and pemetrexed or cisplatin potentially useful in the treatment of EGFR-mutated NSCLC patients, which might delay the appearance of osimertinib resistance with long-lasting effects. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 135-139 31138260-13 2019 CONCLUSIONS: Our results identify a combination between osimertinib and pemetrexed or cisplatin potentially useful in the treatment of EGFR-mutated NSCLC patients, which might delay the appearance of osimertinib resistance with long-lasting effects. osimertinib 200-211 epidermal growth factor receptor Homo sapiens 135-139 31213907-0 2019 Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 10-14 31213907-0 2019 Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 58-62 31213907-2 2019 The aim of this study was to assess the differential clinical outcomes of osimertinib therapy in NSCLC patients with T790M according to the type of activating EGFR mutation, ie, exon 19 deletion or L858R point mutation. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 159-163 31213907-3 2019 Patients and methods: A prospective observational cohort study was conducted to evaluate the efficacy and safety of osimertinib in patients with a major EGFR mutation and T790M-positive advanced NSCLC who had disease progression after first-line EGFR-TKI therapy. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 153-157 31213907-4 2019 The efficacy of osimertinib was evaluated according to the type of EGFR mutation. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 67-71 31213907-12 2019 Conclusion: Investigators should consider the proportions of sensitive EGFR mutation types as a stratification factor in designing or reviewing clinical studies involving osimertinib. osimertinib 171-182 epidermal growth factor receptor Homo sapiens 71-75 31183356-0 2019 Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 88-92 31183356-2 2019 Although clinical trials of AURA series illustrated that non-small cell lung cancer (NSCLC) with EGFR T790M mutation can benefit from osimertinib, only five LSCC patients were enrolled in total; moreover, the efficacy for LSCC was not shown in the results. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 97-101 31183356-4 2019 CASE SUMMARY: We report an LSCC case with T790M-related acquired resistance after treatments with first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and benefited from osimertinib significantly. osimertinib 178-189 epidermal growth factor receptor Homo sapiens 115-119 31183356-4 2019 CASE SUMMARY: We report an LSCC case with T790M-related acquired resistance after treatments with first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and benefited from osimertinib significantly. osimertinib 178-189 epidermal growth factor receptor Homo sapiens 148-152 31183356-14 2019 CONCLUSION: Our findings highlight that EGFR T790M mutation may also be an important acquired drug resistance mechanism for LSCC and offer direct evidence of the efficacy of osimertinib in LSCC with T790M mutation. osimertinib 174-185 epidermal growth factor receptor Homo sapiens 40-44 31043566-5 2019 The model successfully predicted the diverse in vitro and in vivo sensitivities of exon 20 insertion mutants, including a singleton, to osimertinib, a third-generation EGFR-TKI (R 2 = 0.72, P = 0.0037). osimertinib 136-147 epidermal growth factor receptor Homo sapiens 168-172 30131091-10 2019 Moreover, an adenocarcinoma patient harboring concurrent RET fusion and EGFR L858R responded to combinatorial treatment of cabozantinib and osimertinib, with a progression-free survival of 5 months. osimertinib 140-151 epidermal growth factor receptor Homo sapiens 72-76 31033571-0 2019 Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 35-67 30901844-4 2019 Recently, the third generation EGFR TKI osimertinib further revolutionized the therapeutic algorithm of EGFR-mutated NSCLC, but its role in patients harboring EGFR mutations besides exon 19 deletions and/or L858R is largely unknown. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 31-35 30847464-1 2019 BACKGROUND: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). osimertinib 64-75 epidermal growth factor receptor Homo sapiens 142-174 30847464-1 2019 BACKGROUND: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). osimertinib 64-75 epidermal growth factor receptor Homo sapiens 176-180 31205925-0 2019 EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 0-4 31205925-3 2019 Here we reported a case of lung adenocarcinoma patient who progressed on osimertinib with EGFR L718Q mutation in the absence of T790M mutation. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 90-94 31205925-6 2019 This is the first clinical report of the use of the effective EGFR-TKI treatment after L718Q-induced osimertinib resistance. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 62-66 30582282-1 2019 11h is a very potent inhibitor against epidermal growth factor receptor triple mutation L858R/T790M/C797S (EGFRTM ) with 13-fold stronger potency than the FDA-approved osimertinib. osimertinib 168-179 epidermal growth factor receptor Homo sapiens 39-71 31043587-3 2019 Recently, third generation EGFR-TKI osimertinib has been approved and yet its acquired resistance mechanism is not clearly understood. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 27-31 30905617-0 2019 Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). osimertinib 44-55 epidermal growth factor receptor Homo sapiens 109-141 30905617-3 2019 This is an ongoing single arm, prospective, open-label, multicenter, phase II trial to evaluate the efficacy and safety of osimertinib plus bevacizumab combination therapy in EGFR mutation-positive patients with untreated or recurrent non-small-cell lung cancer and pleural and/or pericardial effusion. osimertinib 123-134 epidermal growth factor receptor Homo sapiens 175-179 30872388-1 2019 Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), undergoes significant hepatic elimination. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-48 30872388-1 2019 Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), undergoes significant hepatic elimination. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 50-54 30189719-0 2019 A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 100-104 30189719-14 2019 CONCLUSION: Osimertinib has favorable efficacy in patients with NSCLC harboring T790M, detected from ctDNA with unknown tumor mutation status, in whom disease had progressed during prior EGFR-TKI therapy. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 187-191 30659024-0 2019 Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 112-116 30659024-1 2019 PURPOSE: In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC). osimertinib 129-140 epidermal growth factor receptor Homo sapiens 57-89 30659024-1 2019 PURPOSE: In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC). osimertinib 129-140 epidermal growth factor receptor Homo sapiens 91-95 30659024-1 2019 PURPOSE: In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC). osimertinib 129-140 epidermal growth factor receptor Homo sapiens 226-230 30659024-1 2019 PURPOSE: In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC). osimertinib 129-140 epidermal growth factor receptor Homo sapiens 226-230 30659024-6 2019 Patients receiving SoC EGFR-TKI could cross over to receive osimertinib after independently confirmed objective disease progression with documented postprogression T790M-positive mutation status. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 23-27 31535082-2 2019 Here we show that miR-147b initiates a reversible tolerant-state to the EGFR inhibitor osimertinib in non-small cell lung cancer. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 72-76 30735003-6 2019 METHODS: We retrospectively reviewed the records of patients who had received osimertinib for NSCLC with EGFR T790M. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 105-109 30735003-13 2019 Osimertinib is basically effective for tumors that acquire resistance to EGFR-TKIs as a result of T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 73-77 30821083-0 2019 Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 143-147 30821083-1 2019 BACKGROUND: Osimertinib is recommended for non-small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 92-96 30864291-4 2019 Three of 12 patients who underwent EGFR-TKI therapy immediately after anti-PD-1 antibody treatment experienced osimertinib-induced ILD. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 35-39 31285867-0 2019 Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 66-70 31285867-2 2019 Mutation profiling of tumour DNA in cerebrospinal fluid (CSF) samples can be used to determine the presence of the EGFR T790M resistance mutation, indicating that osimertinib, a CNS-penetrating 3rd generation TKI may be efficacious. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 115-119 31285867-9 2019 Conclusions: Standard-dose osimertinib resulted in a clinically meaningful response in a patient with EGFR T790M-negative 1st generation EGFR TKI refractory leptomeningeal disease. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 102-106 31285867-9 2019 Conclusions: Standard-dose osimertinib resulted in a clinically meaningful response in a patient with EGFR T790M-negative 1st generation EGFR TKI refractory leptomeningeal disease. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 137-141 31027702-11 2019 CONCLUSIONS: The mutational analysis performed on plasma plays a significant role in prognostic stratification, especially for the EGFR activating mutation, since patients with absence or low levels of mutations presented a better outcome to osimertinib. osimertinib 242-253 epidermal growth factor receptor Homo sapiens 131-135 30872380-6 2019 TAS-121 potently inhibited common activating and resistance EGFR mutations to the same extent as another third-generation EGFR-TKI (osimertinib). osimertinib 132-143 epidermal growth factor receptor Homo sapiens 122-126 30651400-1 2019 LESSONS LEARNED: Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted. osimertinib 236-247 epidermal growth factor receptor Homo sapiens 199-203 30651400-1 2019 LESSONS LEARNED: Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted. osimertinib 396-407 epidermal growth factor receptor Homo sapiens 199-203 30651400-2 2019 BACKGROUND: Previous findings suggest the possibility of relatively safe use of osimertinib for patients with T790M-positive non-small-cell lung cancer (NSCLC), with few serious adverse events for the elderly in comparison with conventional endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and with an antitumor effect. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 277-281 30651400-3 2019 METHODS: This phase II study was performed to prospectively investigate the efficacy and safety of osimertinib for elderly patients aged >=75 years with ineffective prior EGFR TKI treatment or with recurrence in T790M EGFR TKI resistance mutation-positive NSCLC. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 174-178 30651400-3 2019 METHODS: This phase II study was performed to prospectively investigate the efficacy and safety of osimertinib for elderly patients aged >=75 years with ineffective prior EGFR TKI treatment or with recurrence in T790M EGFR TKI resistance mutation-positive NSCLC. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 221-225 30651400-12 2019 CONCLUSION: Osimertinib may be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 115-119 30856555-0 2019 The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 21-25 30856555-0 2019 The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 164-168 30856555-1 2019 The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 21-25 30856555-1 2019 The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 98-102 30856555-1 2019 The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 98-102 30856555-2 2019 Osimertinib is now an approved drug for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (first-line) or those who have become resistant to 1st generation EGFR inhibitors through the T790 M mutation (second-line). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 100-104 30856555-2 2019 Osimertinib is now an approved drug for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (first-line) or those who have become resistant to 1st generation EGFR inhibitors through the T790 M mutation (second-line). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 181-185 30856555-6 2019 The current study has demonstrated that osimertinib reduces c-FLIP levels via facilitating its degradation and enhances apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) primarily in NSCLC with activating EGFR mutations. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 240-244 30856555-7 2019 Moreover, modulation of c-FLIP expression levels, to some degree, also alters the sensitivities of EGFR mutant NSCLC cells to undergo osimertinib-induced apoptosis, suggesting that c-FLIP suppression is an important event contributing to the antitumor activity of osimertinib against EGFR mutant NSCLC. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 99-103 30856555-7 2019 Moreover, modulation of c-FLIP expression levels, to some degree, also alters the sensitivities of EGFR mutant NSCLC cells to undergo osimertinib-induced apoptosis, suggesting that c-FLIP suppression is an important event contributing to the antitumor activity of osimertinib against EGFR mutant NSCLC. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 284-288 30856555-7 2019 Moreover, modulation of c-FLIP expression levels, to some degree, also alters the sensitivities of EGFR mutant NSCLC cells to undergo osimertinib-induced apoptosis, suggesting that c-FLIP suppression is an important event contributing to the antitumor activity of osimertinib against EGFR mutant NSCLC. osimertinib 264-275 epidermal growth factor receptor Homo sapiens 99-103 31039766-0 2019 The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 27-31 31039766-3 2019 CASE PRESENTATION: A NSCLC patient with exon 19 deletion (ex19del) of EGFR was treated with osimertinib after multiple lines of treatment and obtained a partial response that lasted over 26 months. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 70-74 31029076-1 2019 BACKGROUND: The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine Kinase Inhibitors (TKIs), to receive a subsequent treatment with osimertinib. osimertinib 286-297 epidermal growth factor receptor Homo sapiens 33-37 31014050-7 2019 The expressions of EGFR and ERBB3 signal pathway related proteins in HCC827 cells treated with overexpression of MALAT1, knockdown of ERBB3 and/or osimertinib treatment were detected by western blot. osimertinib 147-158 epidermal growth factor receptor Homo sapiens 19-23 31014050-14 2019 However, osimertinib downregulated the expressions of p-EGFR, p-ERBB3, p-AKT and p-ERK in ERBB3 deleted cells. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 56-60 30901844-4 2019 Recently, the third generation EGFR TKI osimertinib further revolutionized the therapeutic algorithm of EGFR-mutated NSCLC, but its role in patients harboring EGFR mutations besides exon 19 deletions and/or L858R is largely unknown. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 104-108 30901844-4 2019 Recently, the third generation EGFR TKI osimertinib further revolutionized the therapeutic algorithm of EGFR-mutated NSCLC, but its role in patients harboring EGFR mutations besides exon 19 deletions and/or L858R is largely unknown. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 104-108 30875919-0 2019 Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 94-98 30875919-1 2019 Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 30875919-1 2019 Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 131-135 30875919-1 2019 Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 131-135 30875919-1 2019 Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 131-135 30875919-4 2019 Among several parameters tested, the progression-free survival (PFS) associated with the initial EGFR-TKIs was positively correlated with the PFS after osimertinib treatment (p = 0.021). osimertinib 152-163 epidermal growth factor receptor Homo sapiens 97-101 30875919-6 2019 A multivariate analysis demonstrated that the PFS with initial EGFR-TKIs was significantly related to the PFS with osimertinib treatment (p = 0.035), whereas osimertinib response was significantly related to the PFS and OS with osimertinib treatment (p = 0.016 and p = 0.006, respectively). osimertinib 115-126 epidermal growth factor receptor Homo sapiens 63-67 30875919-7 2019 Our retrospective observations indicate that PFS following the initial EGFR-TKI treatment and the response rate to osimertinib might be promising predictors for effective osimertinib treatment in NSCLC patients with the EGFR-T790M mutation. osimertinib 171-182 epidermal growth factor receptor Homo sapiens 220-224 30875928-1 2019 The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 61-93 30875928-1 2019 The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 95-99 30875928-1 2019 The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 220-224 30875928-3 2019 Osimertinib demonstrated improvement in median progression-free survival (18.9 months vs. 10.2 months; hazard ratio 0.46; 95% CI, 0.37 to 0.57; p < 0.001) and a more favorable toxicity profile due to its lower affinity for wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 236-240 30876460-11 2019 Additionally oleic acid (OA, a kind of MUFA, the SCD1 enzymatic product) abrogates the cytotoxic effect of both Gefitinib and osimertinib in cell lines with EGFR-activating mutations. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 157-161 30881166-0 2019 Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 97-101 30657347-0 2019 Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. osimertinib 8-19 epidermal growth factor receptor Homo sapiens 40-44 30657347-2 2019 Osimertinib is a third-generation oral small molecule inhibitor of EGFR, active against the common targetable activating EGFR mutations in L858R and exon 19 deletion; it also inhibits the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 67-71 30657347-2 2019 Osimertinib is a third-generation oral small molecule inhibitor of EGFR, active against the common targetable activating EGFR mutations in L858R and exon 19 deletion; it also inhibits the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 121-125 30997189-0 2019 Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-20 30997245-0 2019 The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 27-59 30997245-0 2019 The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 61-65 30257889-0 2019 Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 72-76 30257889-1 2019 BACKGROUND: The objective of this study was to assess cost and effectiveness of osimertinib in treating newly diagnosed advanced non-small cell lung cancer with an epidermal growth factor receptor (EGFR) mutation from a public payer"s perspective in the U.S. and China. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 164-196 30257889-1 2019 BACKGROUND: The objective of this study was to assess cost and effectiveness of osimertinib in treating newly diagnosed advanced non-small cell lung cancer with an epidermal growth factor receptor (EGFR) mutation from a public payer"s perspective in the U.S. and China. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 198-202 30819142-0 2019 Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 97-129 30819142-2 2019 Osimertinib is the most recently approved EGFR-TKI, and its usage is increasing in clinical practice for lung cancer patients who have mutations in the EGFR gene. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 42-46 30819142-2 2019 Osimertinib is the most recently approved EGFR-TKI, and its usage is increasing in clinical practice for lung cancer patients who have mutations in the EGFR gene. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 152-156 30828454-0 2019 Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. osimertinib 185-196 epidermal growth factor receptor Homo sapiens 18-50 30863108-1 2019 Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 12-16 30863108-1 2019 Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 45-49 30863108-1 2019 Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 45-49 30863108-11 2019 Conclusion: Our study showed a favorable efficacy of osimertinib in terms of PFS and OS compared to all other EGFR-TKIs in patients with NSCLC harboring activating EGFR mutations. osimertinib 53-64 epidermal growth factor receptor Homo sapiens 164-168 30863108-13 2019 Therefore, osimertinib is indicated as a preferable first-line TKI in patients with activating EGFR-mutated NSCLC. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 95-99 30881166-7 2019 Our case report adds to a growing body of evidence that combination osimertinib and crizotinib should be recommended to EGFR-mutant NSCLC patients with emergent MET amplification as acquired resistance. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 120-124 30718357-3 2019 The compound osimertinib is a third-generation tyrosine kinase inhibitor, which was granted full FDA approval in March 2017 based on targeting EGFR T790M resistance. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 143-147 30302022-4 2019 HCC827GR5 and PC9AZDR7 are EGFR-TKI-resistant clones for gefitinib and osimertinib, respectively. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 27-31 30906765-0 2019 Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 61-93 30639208-0 2019 Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 85-89 30639208-1 2019 PURPOSE: This study aimed to evaluate the cost-effectiveness of osimertinib with gefitinib or erlotinib as first-line and sequential therapy for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in China. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 145-177 30639208-1 2019 PURPOSE: This study aimed to evaluate the cost-effectiveness of osimertinib with gefitinib or erlotinib as first-line and sequential therapy for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in China. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 179-183 30302022-8 2019 In addition, administration of U3-1402 notably repressed growth of EGFR-TKI osimertinib-resistant PC9AZDR7 xenograft tumours, and that PC9AZDR7 cells expressed five times greater cell surface HER3 than PC9 cells. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 67-71 30483795-0 2019 Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba/F3 cells. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 17-21 30483795-2 2019 Afatinib, a second-generation EGFR-TKI and osimertinib, a third-generation EGFR-TKI, are both standard therapies for patients with these types of cancer. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 75-79 30683066-1 2019 BACKGROUND: Osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has become the standard treatment in cases where rebiopsy reveals T790M mutation after the first-line EGFR-TKI treatment. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 106-110 30683066-1 2019 BACKGROUND: Osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has become the standard treatment in cases where rebiopsy reveals T790M mutation after the first-line EGFR-TKI treatment. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 219-223 30774361-2 2019 However, the frequency of T790M resistance mutation acquisition and the efficacy of osimertinib in patients harboring uncommon EGFR mutations, which accounts for approximately 10% of EGFR mutations, remain unclear. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 127-131 30774361-1 2019 Background: Osimertinib is the standard of care for patients with non-small-cell lung cancer (NSCLC) patients harboring acquired EGFR T790M resistance mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 129-133 30774361-2 2019 However, the frequency of T790M resistance mutation acquisition and the efficacy of osimertinib in patients harboring uncommon EGFR mutations, which accounts for approximately 10% of EGFR mutations, remain unclear. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 183-187 30774361-3 2019 Case presentation: We present the case of a 72-year-old Japanese woman with recurrent NSCLC harboring uncommon EGFR mutations, who was subsequently found to have acquired the T790M resistance mutation and was treated with osimertinib. osimertinib 222-233 epidermal growth factor receptor Homo sapiens 111-115 30651547-1 2019 A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 8-12 30651547-1 2019 A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 96-100 30651547-4 2019 Activated AXL was associated with EGFR and HER3 in maintaining cell survival and inducing the emergence of cells tolerant to osimertinib. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 34-38 30651547-5 2019 AXL inhibition reduced the viability of EGFR-mutated lung cancer cells overexpressing AXL that were exposed to osimertinib. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 40-44 30230541-11 2019 During follow-up, one female patient with EGFR exon 19 deletion and NF1 Q1815X comutation showed poor response to EGFR TKIs (Gefitinib and Osimertinib) after disease relapse. osimertinib 139-150 epidermal growth factor receptor Homo sapiens 42-46 30230541-11 2019 During follow-up, one female patient with EGFR exon 19 deletion and NF1 Q1815X comutation showed poor response to EGFR TKIs (Gefitinib and Osimertinib) after disease relapse. osimertinib 139-150 epidermal growth factor receptor Homo sapiens 114-118 30609789-0 2019 First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? osimertinib 59-70 epidermal growth factor receptor Homo sapiens 29-33 30609789-0 2019 First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? osimertinib 59-70 epidermal growth factor receptor Homo sapiens 86-90 30609789-4 2019 Osimertinib is a third-generation EGFR-TKI that still irreversibly inhibits the activity of EGFR after it has acquired the secondary T790M mutation that confers resistance to first- and second-generation drugs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 30609789-4 2019 Osimertinib is a third-generation EGFR-TKI that still irreversibly inhibits the activity of EGFR after it has acquired the secondary T790M mutation that confers resistance to first- and second-generation drugs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 92-96 30609789-6 2019 Although there are five EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) currently available for the treatment of EGFR-mutated lung cancer, the optimal sequence for administration of these drugs remains to be determined. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 138-142 30788361-10 2019 Furthermore, we confirm the emerging role of EGFR p.G724S mutation as a Osimertinib resistence mechanism. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 45-49 31099642-4 2019 Osimertinib has largely displaced first- and second-generation EGFR TKIs, including gefitinib, erlotinib, and afatinib, in the management of EGFR-mutated NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 141-145 30788361-1 2019 We reported the case of a male patient suffering from a metastatic squamous cell carcinoma, harboring a complex inframe deletion in exon 19 of epidermal growth factor receptor (EGFR), treated with erlotinib and osimertinib and subsequently with immunotherapy. osimertinib 211-222 epidermal growth factor receptor Homo sapiens 143-175 30788361-1 2019 We reported the case of a male patient suffering from a metastatic squamous cell carcinoma, harboring a complex inframe deletion in exon 19 of epidermal growth factor receptor (EGFR), treated with erlotinib and osimertinib and subsequently with immunotherapy. osimertinib 211-222 epidermal growth factor receptor Homo sapiens 177-181 30332963-2 2019 Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) shows promising efficacy for LM. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 32-64 29807405-0 2019 Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 77-81 29807405-2 2019 Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 31-35 30332963-2 2019 Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) shows promising efficacy for LM. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 92-96 30111817-3 2019 Here we report that NSCLC cells with acquired resistance to gefitinib or osimertinib (AZD9291) exhibit EMT features, with a decrease in E-cadherin, and increases in vimentin and stemness, without possessing any EGFR secondary mutations. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 211-215 30863565-0 2019 Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 52-84 31292359-4 2019 In a recent clinical trial, an irreversible EGFR-TKI (osimertinib) showed a superior survival benefit with lower toxicity profile. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 44-48 30642539-3 2019 A 67-year-old woman with EGFR-mutated NSCLC received gefitinib and subsequently osimertinib, due to the presence of T790 M at progression. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 25-29 30642539-6 2019 Since this first description of SqCC transformation appearing after treatment with the third-generation TKI osimertinib, other 16 patients, with EGFR-mutated ADK developing a transformation to SqCC histology after treatment with TKIs, were up to now published. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 145-149 30171258-4 2019 As the third generation EGFR TKI, osimertinib, has now been adopted in the first-line setting, the frequency of T790M mutations will significantly decrease in the acquired resistance setting. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 24-28 30171258-5 2019 Previously less common mechanisms of acquired resistance to first generation EGFR TKIs including EMT are now being observed at an increased frequency after osimertinib. osimertinib 156-167 epidermal growth factor receptor Homo sapiens 77-81 30171258-9 2019 TWIST1 overexpression resulted in erlotinib and osimertinib resistance in EGFR-mutant NSCLC cells. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 74-78 30365094-0 2019 Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 53-57 30365094-1 2019 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-76 30365094-1 2019 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 78-82 30365094-1 2019 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 179-183 30365094-3 2019 The present study investigated treatment with osimertinib combined with IR in EGFR T790M non-small cell lung cancer (NCI-H1975) in vitro and in vivo. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 78-82 30365094-5 2019 Furthermore, osimertinib alone or in combination with IR, blocked the phosphorylation of EGFR (Tyr1068/Tyr1173), protein kinase B and extracellular signal-regulated kinase. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 89-93 30365094-7 2019 The results of the present study indicated that osimertinib has therapeutic potential as a radiation-sensitizer in lung cancer cells harboring the EGFR T790M mutation, providing a rationale for clinically combining osimertinib with irradiation in EGFR T790M non-small cell lung cancer. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 147-151 30365094-7 2019 The results of the present study indicated that osimertinib has therapeutic potential as a radiation-sensitizer in lung cancer cells harboring the EGFR T790M mutation, providing a rationale for clinically combining osimertinib with irradiation in EGFR T790M non-small cell lung cancer. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 247-251 30500458-15 2019 Osimertinib is an irreversible type VI inhibitor that forms a covalent bond with C797 of EGFR and is FDA-approved for the treatment of patients with this mutation; type VI inhibitors generally form a covalent adduct with their target protein. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 89-93 30500458-21 2019 Of the approximate three dozen FDA-approved small molecule protein kinase inhibitors, five are type VI irreversible inhibitors and four of them including afatinib, osimertinib, dacomitinib, and neratinib are directed against the ErbB family of receptors (ibrutinib is the fifth and it targets Bruton tyrosine kinase). osimertinib 164-175 epidermal growth factor receptor Homo sapiens 229-233 30457891-0 2018 Safety of osimertinib in EGFR-mutated non-small cell lung cancer. osimertinib 10-21 epidermal growth factor receptor Homo sapiens 25-29 30591099-5 2018 In addition, the third-generation TKI drugs Osimertinib (AZD9291) and Rociletinib (CO-1686) have been developed to further benefit patients with primary TKI resistance caused by T790M mutation of EGFR. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 196-200 30588029-0 2019 Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 24-28 30588029-0 2019 Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 89-93 30588029-2 2019 Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 25-29 30588029-2 2019 Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored. osimertinib 153-164 epidermal growth factor receptor Homo sapiens 25-29 30588029-5 2019 Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 80-84 30588029-5 2019 Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance. osimertinib 140-151 epidermal growth factor receptor Homo sapiens 80-84 30588029-7 2019 EGFR G724S mutation might be associated with osimertinib resistance but more studies about the mechanism should be explored. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 0-4 30442506-0 2018 Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 79-83 30442506-1 2018 Osimertinib has been approved as a first-line treatment for non-small-cell lung cancer (NSCLC) patients whose tumor carries EGFR activation and / or resistant mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 124-128 30642559-0 2019 Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 108-112 30642559-1 2019 Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 121-125 30146570-1 2018 Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. osimertinib 166-177 epidermal growth factor receptor Homo sapiens 0-32 30146570-1 2018 Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. osimertinib 166-177 epidermal growth factor receptor Homo sapiens 34-38 30146570-1 2018 Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. osimertinib 166-177 epidermal growth factor receptor Homo sapiens 227-231 30228210-0 2018 Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 13-17 30228210-1 2018 PURPOSE: Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 146-150 30228210-14 2018 CONCLUSIONS: Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 78-82 30588016-1 2018 Background: Osimertinib is an EGFR-TKI that is selective for both EGFR-TKI-sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 30-34 30588016-1 2018 Background: Osimertinib is an EGFR-TKI that is selective for both EGFR-TKI-sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 66-70 30522170-10 2018 Among 17 EGFR T790M positive patients, 9 received EGFR inhibitor Osimertinib treatment, and 7 of them had good therapeutic response after the treatment. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 9-13 30522170-10 2018 Among 17 EGFR T790M positive patients, 9 received EGFR inhibitor Osimertinib treatment, and 7 of them had good therapeutic response after the treatment. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 50-54 30603652-1 2018 We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective. osimertinib 239-250 epidermal growth factor receptor Homo sapiens 229-233 30603652-1 2018 We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective. osimertinib 302-313 epidermal growth factor receptor Homo sapiens 229-233 30603652-3 2018 Four years after initial diagnosis, EGFR T790M was detected in a metastatic lesion of the right thoracic wall and osimertinib was prescribed. osimertinib 114-125 epidermal growth factor receptor Homo sapiens 36-40 30740431-0 2018 Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? osimertinib 8-19 epidermal growth factor receptor Homo sapiens 23-27 30457891-1 2018 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M acquired mutations, minimizing exposure in EGFR-wild-type tissues. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 48-80 30457891-1 2018 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M acquired mutations, minimizing exposure in EGFR-wild-type tissues. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 82-86 30457891-1 2018 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M acquired mutations, minimizing exposure in EGFR-wild-type tissues. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 154-158 30457891-1 2018 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M acquired mutations, minimizing exposure in EGFR-wild-type tissues. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 154-158 30457891-2 2018 Areas covered: Osimertinib use in EGFR-mutated non-small cell lung cancer patients is described, focusing on safety and tolerability from studies supporting its approval. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 34-38 30457891-3 2018 Expert opinion: Osimertinib demonstrated greater efficacy, including CNS activity, compared to chemotherapy, with a manageable safety profile in pretreated T790M+ EGFR-mutated patients, leading to FDA approval in 2015 within record time in the oncology field. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 163-167 30457891-4 2018 However, the therapeutic strategy in the EGFR-mutated population is changing, following the FLAURA study in untreated EGFR-mutated patients, in which osimertinib improved progression-free survival compared to other TKIs, with a similar toxicity profile but a lower serious adverse event rate. osimertinib 150-161 epidermal growth factor receptor Homo sapiens 41-45 30457891-4 2018 However, the therapeutic strategy in the EGFR-mutated population is changing, following the FLAURA study in untreated EGFR-mutated patients, in which osimertinib improved progression-free survival compared to other TKIs, with a similar toxicity profile but a lower serious adverse event rate. osimertinib 150-161 epidermal growth factor receptor Homo sapiens 118-122 30457891-5 2018 In April 2018, the FDA and EMA approved osimertinib as first-line therapy for EGFR-mutated patients. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 78-82 30457891-8 2018 In the coming years, osimertinib will be consolidated as standard therapy in the EGFR population and in naive and pretreated patients, based on mature survival data and the toxicity profile. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 81-85 29071523-1 2018 PURPOSE: To report a case of a choroidal metastasis from a non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, which responded to Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). osimertinib 171-182 epidermal growth factor receptor Homo sapiens 102-134 29071523-1 2018 PURPOSE: To report a case of a choroidal metastasis from a non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, which responded to Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). osimertinib 171-182 epidermal growth factor receptor Homo sapiens 136-140 29071523-1 2018 PURPOSE: To report a case of a choroidal metastasis from a non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, which responded to Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). osimertinib 171-182 epidermal growth factor receptor Homo sapiens 203-207 29071523-8 2018 CONCLUSION: This report demonstrates that Osimertinib is effective for choroidal metastasis of NSCLC harboring an EGFR-T790M mutation, which has progressed on or after first- or second-generation EGFR-TKI therapy. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 114-118 29071523-8 2018 CONCLUSION: This report demonstrates that Osimertinib is effective for choroidal metastasis of NSCLC harboring an EGFR-T790M mutation, which has progressed on or after first- or second-generation EGFR-TKI therapy. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 196-200 30527177-0 2018 EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 0-4 30244389-1 2018 PURPOSE: Osimertinib, a third-generation irreversible mutant-selective inhibitor of EGFR kinase activity was clinically evaluated in the AURA trials, where it showed high clinical efficacy and a favorable toxicity profile in patients with acquired exon 20-EGFR pT790M mutation. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 84-88 30244389-1 2018 PURPOSE: Osimertinib, a third-generation irreversible mutant-selective inhibitor of EGFR kinase activity was clinically evaluated in the AURA trials, where it showed high clinical efficacy and a favorable toxicity profile in patients with acquired exon 20-EGFR pT790M mutation. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 256-260 30350450-2 2018 Although osimertinib, a third-generation EGFR-TKI, has efficacy against CNS metastases, further treatment modalities are still needed as some of these lesions do not respond to osimertinib, or undergo progression after an initial response to this drug if radiotherapy has already been conducted. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 41-45 30527177-0 2018 EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 141-145 30527177-1 2018 OBJECTIVES: In AURA3 (NCT02151981), osimertinib treatment provided significant clinical benefit compared with platinum-pemetrexed in patients with epidermal growth factor receptor (EGFR) T790M-positive advanced non-small-cell lung cancer (NSCLC), whose tumors had progressed on previous EGFR-tyrosine kinase inhibitor therapy. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 147-179 30527177-1 2018 OBJECTIVES: In AURA3 (NCT02151981), osimertinib treatment provided significant clinical benefit compared with platinum-pemetrexed in patients with epidermal growth factor receptor (EGFR) T790M-positive advanced non-small-cell lung cancer (NSCLC), whose tumors had progressed on previous EGFR-tyrosine kinase inhibitor therapy. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 181-185 30527177-1 2018 OBJECTIVES: In AURA3 (NCT02151981), osimertinib treatment provided significant clinical benefit compared with platinum-pemetrexed in patients with epidermal growth factor receptor (EGFR) T790M-positive advanced non-small-cell lung cancer (NSCLC), whose tumors had progressed on previous EGFR-tyrosine kinase inhibitor therapy. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 287-291 30527179-0 2018 Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 21-25 30527179-0 2018 Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 92-96 30527179-2 2018 Osimertinib, a 3 G EGFR-TKI, is a standard of care in this situation, but eventually also evokes resistance, reportedly due to some tertiary EGFR mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 19-23 30527179-2 2018 Osimertinib, a 3 G EGFR-TKI, is a standard of care in this situation, but eventually also evokes resistance, reportedly due to some tertiary EGFR mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 141-145 30527179-6 2018 MATERIALS AND METHODS: We used literature search to identify EGFR mutations at codons L718, G724, L792, G796, and C797 as mechanisms of osimertinib resistance in the presence of T790 M. These mutations were introduced into Ba/F3 cells in cis with activating EGFR mutations but not with T790 M; inhibitory effects of five EGFR-TKIs were evaluated. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 61-65 30295016-0 2018 Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 85-89 30392443-0 2018 Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 83-87 30392443-1 2018 INTRODUCTION: Treatment paradigms for EGFR-mutated non-small cell lung cancer (NSCLC) have successfully evolved since the introduction of osimertinib. osimertinib 138-149 epidermal growth factor receptor Homo sapiens 38-42 30392443-2 2018 The detection of EGFR T790M mutation in plasma or tumor samples obtained at disease progression to first-/second-generation EGFR inhibitors is mandatory for osimertinib prescription. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 17-21 30392443-2 2018 The detection of EGFR T790M mutation in plasma or tumor samples obtained at disease progression to first-/second-generation EGFR inhibitors is mandatory for osimertinib prescription. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 124-128 30481207-8 2018 In these two cases, longitudinal analysis showed earlier biopsies harbored EGFR T790M, which was undetectable following osimertinib treatment. osimertinib 120-131 epidermal growth factor receptor Homo sapiens 75-79 30445769-5 2018 Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against EGFR-mutated lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 31-35 30445769-5 2018 Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against EGFR-mutated lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 110-114 30405134-0 2018 Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 11-15 30405134-7 2018 Our data provide a mechanistic basis for the osimertinib-induced selection of EGFRG724S-mutant clones and a rationale to treat these patients with clinically approved second-generation EGFR inhibitors. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 78-82 30400855-0 2018 Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 96-100 30400855-1 2018 BACKGROUND: Among non-small cell lung cancer (NSCLC) patients with acquired T790 M mutation resistance to first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), 71% are likely to benefit from osimertinib. osimertinib 225-236 epidermal growth factor receptor Homo sapiens 183-187 30397287-0 2018 The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 25-29 30397287-2 2018 Therefore, this study evaluated the correlation between treatment outcome and activating EGFR mutations (act-EGFR) and T790M in cfDNA in patients with advanced NSCLC given osimertinib. osimertinib 172-183 epidermal growth factor receptor Homo sapiens 89-93 30397287-2 2018 Therefore, this study evaluated the correlation between treatment outcome and activating EGFR mutations (act-EGFR) and T790M in cfDNA in patients with advanced NSCLC given osimertinib. osimertinib 172-183 epidermal growth factor receptor Homo sapiens 109-113 30397287-9 2018 CONCLUSION: act-EGFR MAF and T790M/act-EGFR MAF ratio are potential markers of outcome in patients treated with osimertinib. osimertinib 112-123 epidermal growth factor receptor Homo sapiens 16-20 30397287-9 2018 CONCLUSION: act-EGFR MAF and T790M/act-EGFR MAF ratio are potential markers of outcome in patients treated with osimertinib. osimertinib 112-123 epidermal growth factor receptor Homo sapiens 39-43 30224350-1 2018 The EGFR inhibitor osimertinib may be an effective therapy for patients with untreated non-small cell lung cancer who have brain metastases. osimertinib 19-30 epidermal growth factor receptor Homo sapiens 4-8 30197264-0 2018 Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 32-36 30197264-0 2018 Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 94-98 30197264-2 2018 A third-generation EGFR-TKI, osimertinib, demonstrated durable efficacy with mild adverse events in a phase III trial and is considered a novel standard regimen. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 19-23 30197264-5 2018 AIMS: The aim of the present single-arm, phase Ib study is to assess the tolerability of osimertinib combined with ramucirumab in patients with EGFR-mutated, T790M+ lung cancer with progression during EGFR-TKI therapy. osimertinib 89-100 epidermal growth factor receptor Homo sapiens 144-148 30197264-5 2018 AIMS: The aim of the present single-arm, phase Ib study is to assess the tolerability of osimertinib combined with ramucirumab in patients with EGFR-mutated, T790M+ lung cancer with progression during EGFR-TKI therapy. osimertinib 89-100 epidermal growth factor receptor Homo sapiens 201-205 30336693-0 2018 Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 68-72 30336693-1 2018 AIM: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. osimertinib 140-151 epidermal growth factor receptor Homo sapiens 41-45 30368417-0 2018 Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 97-101 30368417-0 2018 Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 131-135 30073261-0 2018 Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. osimertinib 138-149 epidermal growth factor receptor Homo sapiens 79-83 30429004-0 2018 Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 57-61 30429004-1 2018 INTRODUCTION: Osimertinib improves progression-free survival in previously untreated EGFR-positive advanced non-small cell lung cancer (NSCLC) patients, with marked intracranial response rates. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 85-89 30429004-4 2018 METHODS: A Markov model was developed to project the outcomes and direct medical costs of initial treatment with osimertinib or current standard-of-care (SoC) EGFR TKIs, gefinitib or afatinib, in patients with previously untreated EGFR-mutant advanced NSCLC. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 231-235 30429004-7 2018 RESULTS: Initial treatment with osimertinib was associated with a gain of 0.79 QALY [95% confidence interval (CI), 0.74 to 0.83] at an incremental cost of $176,394 CAD (95% CI, 176,383 to 176,405) vs. SoC EGFR TKI (incremental cost-effectiveness ratio [ICER]: $223,133/QALY gained; 95%CI, 198,144 to 252,805). osimertinib 32-43 epidermal growth factor receptor Homo sapiens 205-209 30429004-10 2018 CONCLUSION: At the current marketed price, first-line osimertinib therapy in patients with advanced EGFR-mutant lung adenocarcinoma is not cost-effective in Canada. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 100-104 30408830-0 2018 [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 47-51 30368410-0 2018 Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 100-104 30408830-6 2018 This article elucidates the developmental state of third generation EGFR-TKIs with its focus on Osimertinib, the first and currently the only compound in this class which is approved in Germany. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 68-72 30079781-4 2018 Expert commentary: Osimertinib is the current treatment option for T790M mutation positive NSCLC after progression to first or second-generation EGFR TKIs, with activity also on brain metastasis. osimertinib 19-30 epidermal growth factor receptor Homo sapiens 145-149 30323297-4 2018 Non-small cell lung cancer (NSCLC) patients with EGFR mutations develop acquired resistance to first (erlotinib)- and third (osimertinib)-generation TKIs. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 49-53 30323297-6 2018 Additionally, Raman difference spectra detected the response of NSCLC cells with T790M EGFR mutation to second- (neratinib) and third-generation (osimertinib) TKIs, and the resistance of cells with T790M/C797S EGFR mutation to osimertinib. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 87-91 30323297-6 2018 Additionally, Raman difference spectra detected the response of NSCLC cells with T790M EGFR mutation to second- (neratinib) and third-generation (osimertinib) TKIs, and the resistance of cells with T790M/C797S EGFR mutation to osimertinib. osimertinib 227-238 epidermal growth factor receptor Homo sapiens 87-91 30310765-5 2018 After the resistance of chemotherapy, the EGFR-T790M mutation by liquid biopsy was detected and treated him with osimertinib, which resulted in a clinical response. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 42-46 29228521-1 2018 PURPOSE: Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 9-41 29228521-1 2018 PURPOSE: Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 43-47 29228521-3 2018 Materials and Methods: Advanced EGFR-mutant lung adenocarcinoma patients with positive T790M mutation in tumor were retrospectively enrolled and observed to determine the outcomes of osimertinib treatment. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 32-36 29618075-2 2018 Osimertinib may be efficacious if those patients become resistant to the 1st-line EGFR-TKI because of the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 82-86 29721756-1 2018 Osimertinib is a standard second-line therapy for patients who develop EGFR Thr790Met resistance mutation after treatment with first-line epidermal growth factor receptor tyrosine kinase inhibitors. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 71-75 29721756-4 2018 In the present case report, a 62-year-old Japanese woman received osimertinib as the sixth-line therapy for non-small cell lung carcinoma harboring EGFR Thr790Met-mutation. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 148-152 30197172-0 2018 CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 31-35 30244855-0 2018 Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 30-34 30268482-3 2018 T790M mutations represent a major resistance mechanism to EGFR-TKIs but can be overcome using osimertinib. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 58-62 30288054-2 2018 Drugs that target epidermal growth factor receptor (EGFR) mutations (eg, gefitinib, erlotinib, icotinib, and osimertinib) are among the most commonly used targeted therapies. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 18-50 30288054-2 2018 Drugs that target epidermal growth factor receptor (EGFR) mutations (eg, gefitinib, erlotinib, icotinib, and osimertinib) are among the most commonly used targeted therapies. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 52-56 30059262-2 2018 We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 188-192 30059262-2 2018 We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 269-273 30237726-3 2018 We report here that an non-small-cell lung cancer patient with the EGFR mutant T790M showed a programmed cell death ligand 1 (PD-L1) expression level that increased from <25% to >90% after eighth-line osimertinib therapy. osimertinib 207-218 epidermal growth factor receptor Homo sapiens 67-71 30233215-0 2018 Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report. osimertinib 114-125 epidermal growth factor receptor Homo sapiens 65-69 30233215-1 2018 Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 104-136 30233215-1 2018 Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 138-142 30233215-3 2018 Herein, we report a case of a lung cancer patient harboring triple EGFR mutations of L858R, T790M, and cis-C797S who was treated with a combination of osimertinib, bevacizumab, and brigatinib. osimertinib 151-162 epidermal growth factor receptor Homo sapiens 67-71 30194172-0 2018 Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 86-90 30194172-0 2018 Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 131-135 30194172-2 2018 PATIENTS AND METHODS: A total of 77 patients with advanced non-small cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation and treated with osimertinib were reviewed. osimertinib 180-191 epidermal growth factor receptor Homo sapiens 142-146 30194172-8 2018 Additionally, the maximum grade of EGFR-TKI-related AEs associated with osimertinib in the EG was significantly lower than that of the initial EGFR-TKI treatment (p=0.03). osimertinib 72-83 epidermal growth factor receptor Homo sapiens 35-39 30194172-9 2018 CONCLUSION: Osimertinib is a safe and effective treatment option for elderly patients with advanced NSCLC who harbor the EGFR mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 121-125 29857056-0 2018 EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. osimertinib 118-129 epidermal growth factor receptor Homo sapiens 0-4 30151614-0 2018 Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 84-88 30151614-1 2018 Osimertinib is the best treatment choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 59-91 30151614-1 2018 Osimertinib is the best treatment choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 93-97 30151614-1 2018 Osimertinib is the best treatment choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 209-213 30151614-4 2018 Here, we report on a unique case of response to osimertinib rechallenge after intervening chemotherapy in an EGFR T790M-positive NSCLC patient pretreated with the sequence erlotinib-osimertinib. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 109-113 30151614-4 2018 Here, we report on a unique case of response to osimertinib rechallenge after intervening chemotherapy in an EGFR T790M-positive NSCLC patient pretreated with the sequence erlotinib-osimertinib. osimertinib 182-193 epidermal growth factor receptor Homo sapiens 109-113 29704676-0 2018 Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 34-38 30153097-0 2018 CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 131-135 30153097-1 2018 Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 164-168 30153097-11 2018 Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 67-71 30104348-6 2018 Our drug inhibition studies indicate that these activating insertion mutations respond more favorably to osimertinib, a recently Food and Drug Administration-approved EGFR inhibitor for T790M-positive patients with lung cancer. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 167-171 30127621-5 2018 Osimertinib is a potent and irreversible third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 123-127 30127622-0 2018 The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 125-129 29775809-1 2018 INTRODUCTION: Osimertinib is an oral, potent, irreversible third-generation EGFR tyrosine kinase inhibitor approved for the treatment of T790M-positive NSCLC patients who failed first- or second-generation EGFR tyrosine kinase inhibitors. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 76-80 29775809-1 2018 INTRODUCTION: Osimertinib is an oral, potent, irreversible third-generation EGFR tyrosine kinase inhibitor approved for the treatment of T790M-positive NSCLC patients who failed first- or second-generation EGFR tyrosine kinase inhibitors. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 206-210 29775809-5 2018 METHODS: We retrospectively analyzed 74 EGFR T790M mutant NSCLC patients treated with osimertinib. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 40-44 29852038-0 2018 Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 79-83 29852038-2 2018 Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations, has recently shown improved clinical outcomes compared with gefitinib and erlotinib for treatment-naive patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 134-138 29852038-3 2018 Objective: The aim of this study was to assess the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated NSCLC. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 131-135 30049375-0 2018 Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 21-25 30049375-0 2018 Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 135-139 29857056-0 2018 EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. osimertinib 118-129 epidermal growth factor receptor Homo sapiens 87-91 29857056-1 2018 BACKGROUND: The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M mutation. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 33-37 29857056-1 2018 BACKGROUND: The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M mutation. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 157-161 29857056-11 2018 CONCLUSIONS: The EGFR L858R/T790M/L792H and L858R/T790M/G796R mutations conferred resistance to osimertinib both in vitro and in silico. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 17-21 29883838-8 2018 Multiple patients treated with combination therapy targeting EGFR and the acquired fusion had clinical benefit, including one patient with osimertinib resistance due to an acquired PLEKHA7-ALK fusion achieving a durable partial response with combination of full-dose osimertinib and alectinib. osimertinib 267-278 epidermal growth factor receptor Homo sapiens 61-65 29907952-0 2018 BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 63-67 29907952-1 2018 The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 21-53 29907952-1 2018 The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 55-59 29907952-1 2018 The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 167-171 29907952-5 2018 Here, we show for the first time that a NSCLC patient harboring the EGFR L858R/T790M mutations, as well as the BIM deletion polymorphism, exhibited poor clinical outcomes with osimertinib treatment. osimertinib 176-187 epidermal growth factor receptor Homo sapiens 68-72 30039345-0 2018 Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 27-31 30039345-0 2018 Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 114-118 30039345-2 2018 OBJECTIVE: To assess the clinical efficacy of osimertinib, a third-generation tyrosine-kinase inhibitor (TKI), in patients with epidermal growth-factor receptor (EGFR)-mutated NSCLCs and LM. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 128-160 30039345-2 2018 OBJECTIVE: To assess the clinical efficacy of osimertinib, a third-generation tyrosine-kinase inhibitor (TKI), in patients with epidermal growth-factor receptor (EGFR)-mutated NSCLCs and LM. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 162-166 30039345-3 2018 PATIENTS AND METHODS: Retrospective study of NSCLC patients with osimertinib-treated EGFR-mutated NSCLC and LM. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 85-89 30039345-9 2018 At osimertinib initiation, 13 (65%) patients harbored the EGFR-T790M-resistance mutation. osimertinib 3-14 epidermal growth factor receptor Homo sapiens 58-62 30055587-3 2018 METHODS: We retrospectively analyzed 142 patients with EGFR-mutation positive advanced or recurrent lung adenocarcinoma who were administered gefitinib, erlotinib, afatinib, and osimertinib. osimertinib 178-189 epidermal growth factor receptor Homo sapiens 55-59 30667181-2 2018 Osimertinib may be efficacious if these patients become resistant to the 1st-line EGFR-TKI because of the T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 82-86 30128066-1 2018 The first evidence of osimertinib resistance mediated by the epidermal growth factor receptor (EGFR) mutation C797S was reported three years ago. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 61-93 30128066-1 2018 The first evidence of osimertinib resistance mediated by the epidermal growth factor receptor (EGFR) mutation C797S was reported three years ago. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 95-99 30018881-6 2018 Osimertinib has emerged as a third-generation EGFR TKI with proven activity in the front-line setting as well as in patients with a T790M acquired resistance mutation with remarkable CNS activity. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 46-50 29789220-0 2018 ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. osimertinib 53-64 epidermal growth factor receptor Homo sapiens 83-87 29858019-0 2018 Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 127-131 29650685-4 2018 Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S. Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 137-141 29650685-4 2018 Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S. Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 137-141 29650685-4 2018 Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S. Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 137-141 28565936-0 2018 Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 75-107 28565936-1 2018 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-66 28565936-1 2018 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 68-72 28565936-1 2018 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 147-151 28565936-4 2018 Osimertinib is selective for mutated forms of EGFR, including the TKI-sensitizing mutations L858R and exon 19 deletions, as well as the acquired T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 46-50 28565936-10 2018 An ongoing study evaluating osimertinib versus first-generation TKIs as first-line treatment for patients with EGFR mutation-positive NSCLC may help to define the role of osimertinib as front-line therapy. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 111-115 28565936-10 2018 An ongoing study evaluating osimertinib versus first-generation TKIs as first-line treatment for patients with EGFR mutation-positive NSCLC may help to define the role of osimertinib as front-line therapy. osimertinib 171-182 epidermal growth factor receptor Homo sapiens 111-115 30174832-3 2018 Osimertinib is a novel irreversible, covalent third-generation EGFR-TKI and potent inhibitor of EGFR T790M mutation, the most common mechanism of acquired resistance to first-generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 63-67 30174832-3 2018 Osimertinib is a novel irreversible, covalent third-generation EGFR-TKI and potent inhibitor of EGFR T790M mutation, the most common mechanism of acquired resistance to first-generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 96-100 30174832-3 2018 Osimertinib is a novel irreversible, covalent third-generation EGFR-TKI and potent inhibitor of EGFR T790M mutation, the most common mechanism of acquired resistance to first-generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 96-100 30174832-4 2018 Several trials have consistently demonstrated the superior clinical activity and safety of osimertinib in patients with advanced NSCLC and acquired EGFR T790M mutation after treatment with a first-generation EGFR-TKI. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 148-152 30174832-4 2018 Several trials have consistently demonstrated the superior clinical activity and safety of osimertinib in patients with advanced NSCLC and acquired EGFR T790M mutation after treatment with a first-generation EGFR-TKI. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 208-212 30158414-0 2018 [Osimertinib for an Elderly Patient with Adenocarcinoma of the Lung Harboring EGFR T790M Mutation Diagnosed Using a Pleural Fluid Cell Block]. osimertinib 1-12 epidermal growth factor receptor Homo sapiens 78-82 30158414-6 2018 Re-evaluation of the left pleural effusion upon failure of osimertinib treatment revealed EGFR T790M mutation negativity. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 90-94 30158414-7 2018 Hence this report summarizes the case of osimertinib therapy being administered to a 90-year-old patient who had EGFR T790M mutation positivity based on a pleural fluid cell block. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 113-117 30158416-1 2018 Osimertinib is a highly active agent for patients with progression of lung cancer despite epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 90-122 30158416-1 2018 Osimertinib is a highly active agent for patients with progression of lung cancer despite epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 124-128 29858019-4 2018 Although he was irresponsive to the first generation TKI gefitinib, he demonstrated sustained disease control to osimertinib, suggesting that this complex is an activating mutation of EGFR and can be suppressed by osimertinib. osimertinib 214-225 epidermal growth factor receptor Homo sapiens 184-188 29858020-14 2018 A third-generation EGFR-TKI, osimertinib, was strongly associated with brain metastasis-free survival as well as other survival indicators in patients with EGFR-mutant lung adenocarcinoma. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 19-23 29858020-14 2018 A third-generation EGFR-TKI, osimertinib, was strongly associated with brain metastasis-free survival as well as other survival indicators in patients with EGFR-mutant lung adenocarcinoma. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 156-160 29858027-0 2018 Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 70-74 29858027-13 2018 CONCLUSIONS: Osimertinib had higher response rate, longer PFS and milder side effects than docetaxel-bevacizumab in third-line therapy in patients with EGFR T790 M positive advanced NSCLC. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 152-156 30045282-0 2018 A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment? osimertinib 103-114 epidermal growth factor receptor Homo sapiens 81-85 30045282-14 2018 CONCLUSIONS: Osimertinib was shown to be the best agent to achieve the longest PFS in NSCLC patients with an activating EGFR mutation. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 120-124 29858019-4 2018 Although he was irresponsive to the first generation TKI gefitinib, he demonstrated sustained disease control to osimertinib, suggesting that this complex is an activating mutation of EGFR and can be suppressed by osimertinib. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 184-188 29963252-1 2018 Osimertinib prolongs progression-free survival (PFS) in patients with metastatic, epidermal growth factor receptor (EGFR) T790M-mutated, non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 82-114 30034635-1 2018 Background: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 103-135 30034635-1 2018 Background: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 137-141 30034636-0 2018 Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 13-17 30034636-6 2018 After the development of resistance to gefitinib, the EGFR-TKI osimertinib was safely administered until disease progression without recurrence of the coagulation abnormality. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 54-58 30034636-7 2018 This case suggests that gefitinib followed by osimertinib may be a safe and effective treatment option for patients with EGFR mutation-positive lung cancer who experience disabling cerebral infarction due to Trousseau syndrome. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 121-125 29963252-1 2018 Osimertinib prolongs progression-free survival (PFS) in patients with metastatic, epidermal growth factor receptor (EGFR) T790M-mutated, non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 116-120 29963252-1 2018 Osimertinib prolongs progression-free survival (PFS) in patients with metastatic, epidermal growth factor receptor (EGFR) T790M-mutated, non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 189-193 29930751-1 2018 Background: Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 68-100 29922072-1 2018 Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against EGFR T790M resistance mutation-positive non-small cell lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 138-142 29930751-1 2018 Background: Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 102-106 29930751-1 2018 Background: Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 150-154 29866661-0 2018 A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 111-115 29848711-0 2018 Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 93-97 29848711-1 2018 BACKGROUND/AIM: Osimertinib has demonstrated promising efficacy in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC). osimertinib 16-27 epidermal growth factor receptor Homo sapiens 81-113 29848711-1 2018 BACKGROUND/AIM: Osimertinib has demonstrated promising efficacy in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC). osimertinib 16-27 epidermal growth factor receptor Homo sapiens 115-119 29848711-3 2018 PATIENTS AND METHODS: The medical records of all patients treated with osimertinib for advanced NSCLC with EGFR T790M between April 2016 and July 2017 at our Institution were retrospectively reviewed. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 107-111 29524556-0 2018 Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. osimertinib 148-159 epidermal growth factor receptor Homo sapiens 21-25 29697876-0 2018 Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 38-42 29697876-3 2018 Osimertinib, a third-generation EGFR-TKI that can inhibit the kinase even when the common resistance-conferring Thr790Met (T790M) mutation is present, is a promising therapeutic option for patients whose disease has progressed after first-line EGFR-TKI treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 32-36 29697876-3 2018 Osimertinib, a third-generation EGFR-TKI that can inhibit the kinase even when the common resistance-conferring Thr790Met (T790M) mutation is present, is a promising therapeutic option for patients whose disease has progressed after first-line EGFR-TKI treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 244-248 29697876-10 2018 The safety and efficacy results in this subanalysis are consistent with the results of the overall AURA3 study, and support the use of osimertinib in Japanese patients with EGFR T790M mutation-positive NSCLC whose disease has progressed following first-line EGFR-TKI treatment. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 173-177 29872644-5 2018 A biopsy of a location in the thorax revealed the presence of an EGFR-T790M mutation associated with acquired resistance, after which treatment with osimertinib was started. osimertinib 149-160 epidermal growth factor receptor Homo sapiens 65-69 30174832-5 2018 Recently, the efficacy of osimertinib in a first-line setting was demonstrated to be clearly superior to standard-first line treatment in patients with EGFR-mutant NSCLC regardless of T790M mutation status. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 152-156 29998228-0 2018 Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 47-51 29998228-7 2018 This review summarizes osimertinib"s pharmacology, pharmacokinetics, safety, side effects and clinical utility in the treatment of EGFR-mutated advanced NSCLC. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 131-135 29505901-0 2018 Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 81-85 29505901-1 2018 INTRODUCTION: Osimertinib is standard treatment for patients with advanced EGFR T790M-mutated non-small-cell lung cancer who have been pre-treated with EGFR-tyrosine kinase inhibitors (TKIs). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 75-79 29505901-1 2018 INTRODUCTION: Osimertinib is standard treatment for patients with advanced EGFR T790M-mutated non-small-cell lung cancer who have been pre-treated with EGFR-tyrosine kinase inhibitors (TKIs). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 152-156 29505901-13 2018 CONCLUSION: Plasma genotyping using digital polymerase chain reaction is clinically useful for the selection of patients who had progressed during first-line EGFR-TKI therapy for treatment with osimertinib. osimertinib 194-205 epidermal growth factor receptor Homo sapiens 158-162 29526823-0 2018 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 39-43 29526823-0 2018 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 127-131 29526823-1 2018 INTRODUCTION: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 71-75 29526823-2 2018 The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models. osimertinib 79-90 epidermal growth factor receptor Homo sapiens 60-64 29526823-2 2018 The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models. osimertinib 79-90 epidermal growth factor receptor Homo sapiens 169-173 29526823-7 2018 CONCLUSIONS: We showed that a dual vertical EGFR blockade with osimertinib plus selumetinib/cetuximab is a novel effective therapeutic option in EGFR-mutated NCLC and that hedgehog pathway activation and its interplay with MAPK is involved in resistance to these combination treatments. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 44-48 29526823-7 2018 CONCLUSIONS: We showed that a dual vertical EGFR blockade with osimertinib plus selumetinib/cetuximab is a novel effective therapeutic option in EGFR-mutated NCLC and that hedgehog pathway activation and its interplay with MAPK is involved in resistance to these combination treatments. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 145-149 29596911-0 2018 Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 140-144 29879078-2 2018 Osimertinib, a 3rd-generation EGFR-TKI, has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 30-34 29879078-2 2018 Osimertinib, a 3rd-generation EGFR-TKI, has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 84-88 29879078-3 2018 In this study, we prospectively investigate the efficacy and safety of osimertinib in elderly patients aged >=75 years, with ineffective prior EGFR-TKI treatment or with recurrence of EGFR-TKI mutation-positive or T790M mutation-positive nonsmall-cell lung cancer. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 187-191 29700687-5 2018 Emerging evidence indicates that the second- and third-generation EGFR TKIs, afatinib and osimertinib, effectively penetrate the blood-brain barrier, and therefore represent viable treatment options for CNS lesions, and can reduce the risk of CNS progression. osimertinib 90-101 epidermal growth factor receptor Homo sapiens 66-70 29754184-2 2018 Fortunately, newly developed, mutant-selective EGFR-TKIs against T790M have been proven as an effective therapeutic approach although only osimertinib has received the FDA approval until now. osimertinib 139-150 epidermal growth factor receptor Homo sapiens 47-51 29673089-0 2018 Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 44-48 29673089-3 2018 A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239-2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. osimertinib 153-164 epidermal growth factor receptor Homo sapiens 76-80 29928211-2 2018 We herein report a case of pulmonary adenocarcinoma with EGFR mutation (exon 19 deletion and T790M) that acquired resistance to osimertinib treatment because of transformation into small-cell lung carcinoma (SCLC). osimertinib 128-139 epidermal growth factor receptor Homo sapiens 57-61 29136465-2 2018 The current third-generation EGFR small-molecule inhibitors, especially osimertinib, are at the forefront clinically for treatment of patients with NSCLC. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 29-33 29930751-1 2018 Background: Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 150-154 29930751-12 2018 Conclusion: Changes of T790M in serum/plasma in EGFR-mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 48-52 29468841-1 2018 Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 69-101 29951342-10 2018 The EGFR T790M and C797G mutations occur in cis is a critical mechanism of resistance to osimertinib therapy. osimertinib 89-100 epidermal growth factor receptor Homo sapiens 4-8 29468841-1 2018 Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 103-107 29425688-2 2018 OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation. osimertinib 0-3 epidermal growth factor receptor Homo sapiens 97-101 29703542-0 2018 Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 97-101 29703545-0 2018 Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 50-54 29703545-0 2018 Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 136-140 29703546-0 2018 Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 60-64 29703546-0 2018 Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 149-153 29483211-0 2018 Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 68-72 29483211-0 2018 Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 119-123 29483211-4 2018 Osimertinib is a third-generation EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M; however, the activity of osimertinib in EGFR Ex20Ins NSCLC has yet to be fully assessed. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 29483211-4 2018 Osimertinib is a third-generation EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M; however, the activity of osimertinib in EGFR Ex20Ins NSCLC has yet to be fully assessed. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 98-102 29483211-4 2018 Osimertinib is a third-generation EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M; however, the activity of osimertinib in EGFR Ex20Ins NSCLC has yet to be fully assessed. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 98-102 29483211-6 2018 We report that osimertinib and AZ5104 inhibit signaling pathways and cellular growth in Ex20Ins mutant cell lines in vitro and demonstrate sustained tumor growth inhibition of EGFR-mutant tumor xenograft harboring the most prevalent Ex20Ins in vivo The antitumor activity of osimertinib and AZ5104 in NSCLC harboring EGFR Ex20Ins is further described herein using a series of patient-derived xenograft models. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 176-180 29483211-6 2018 We report that osimertinib and AZ5104 inhibit signaling pathways and cellular growth in Ex20Ins mutant cell lines in vitro and demonstrate sustained tumor growth inhibition of EGFR-mutant tumor xenograft harboring the most prevalent Ex20Ins in vivo The antitumor activity of osimertinib and AZ5104 in NSCLC harboring EGFR Ex20Ins is further described herein using a series of patient-derived xenograft models. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 317-321 29483211-7 2018 Together these data support clinical testing of osimertinib in patients with EGFR Ex20Ins NSCLC. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 77-81 29425688-4 2018 Resistance mechanisms to OSI, such as additional mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance. osimertinib 25-28 epidermal growth factor receptor Homo sapiens 61-65 29641535-1 2018 AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 69-73 29641535-1 2018 AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 136-140 29325035-10 2018 Studying 25 patients positive for EGFR T790M that developed resistance to osimertinib, 15 resistance mechanisms could be detected including tertiary EGFR mutations (C797S, Q791P) and mutations or amplifications of non-EGFR genes, some of which could be detected pretreatment or months before progression. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 34-38 29325035-10 2018 Studying 25 patients positive for EGFR T790M that developed resistance to osimertinib, 15 resistance mechanisms could be detected including tertiary EGFR mutations (C797S, Q791P) and mutations or amplifications of non-EGFR genes, some of which could be detected pretreatment or months before progression. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 149-153 29325035-10 2018 Studying 25 patients positive for EGFR T790M that developed resistance to osimertinib, 15 resistance mechanisms could be detected including tertiary EGFR mutations (C797S, Q791P) and mutations or amplifications of non-EGFR genes, some of which could be detected pretreatment or months before progression. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 149-153 29862229-4 2018 Third-generation EGFR-TKIs, including osimertinib and rociletinib, target this epigenic mutation, thus re-sensitizing cancer cells to EGFR-TKI inhibition. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 17-21 29862229-4 2018 Third-generation EGFR-TKIs, including osimertinib and rociletinib, target this epigenic mutation, thus re-sensitizing cancer cells to EGFR-TKI inhibition. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 134-138 29862229-5 2018 Osimertinib to date represents the standard of care in EGFR-mutant tumors after failure of first-line EGFR-TKIs by over-performing platinum-based chemotherapy in the recently reported AURA-3 randomized phase III clinical trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 55-59 29862229-5 2018 Osimertinib to date represents the standard of care in EGFR-mutant tumors after failure of first-line EGFR-TKIs by over-performing platinum-based chemotherapy in the recently reported AURA-3 randomized phase III clinical trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 29363250-0 2018 Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 29-61 29363250-1 2018 Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 38-70 29363250-1 2018 Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 72-76 29363250-1 2018 Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 124-128 29363250-2 2018 The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 154-158 29363250-11 2018 Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation-positive status was determined from cytology samples. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 99-103 29363250-11 2018 Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation-positive status was determined from cytology samples. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 150-154 29477930-7 2018 Among T790M-positive patients, the third-generation EGFR TKI, osimertinib, has shown superiority over both platinum-doublet chemotherapy and 1st generation EGFR TKI in randomized clinical trials, and exhibits enhanced in vitro selectivity for mutant EGFR receptors and pharmacokinetics compared to earlier-generation TKIs. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 52-56 29477930-7 2018 Among T790M-positive patients, the third-generation EGFR TKI, osimertinib, has shown superiority over both platinum-doublet chemotherapy and 1st generation EGFR TKI in randomized clinical trials, and exhibits enhanced in vitro selectivity for mutant EGFR receptors and pharmacokinetics compared to earlier-generation TKIs. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 156-160 29477930-7 2018 Among T790M-positive patients, the third-generation EGFR TKI, osimertinib, has shown superiority over both platinum-doublet chemotherapy and 1st generation EGFR TKI in randomized clinical trials, and exhibits enhanced in vitro selectivity for mutant EGFR receptors and pharmacokinetics compared to earlier-generation TKIs. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 156-160 29247383-0 2018 Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 132-136 29247383-10 2018 CONCLUSIONS: In this indirect comparison, osimertinib showed a statistically significant improvement in efficacy outcomes versus platinum-based doublet chemotherapy in patients with EGFRm T790M NSCLC who had progressed after EGFR-TKI therapy. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 182-186 29719432-3 2018 In patients with resistance to tkis caused by the EGFR T790M mutation, the third-generation tki osimertinib is now the standard of care. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 50-54 29269665-0 2018 EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib. osimertinib 137-148 epidermal growth factor receptor Homo sapiens 0-4 29239002-1 2018 Osimertinib is an oral, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 68-100 29239002-1 2018 Osimertinib is an oral, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 29571986-0 2018 Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 9-13 29571986-11 2018 In vitro functional studies demonstrated that EGFR-L858R/L718V confers resistance to osimertinib, but retains sensitivity to the second generation TKI afatinib. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 46-50 29571986-13 2018 We also demonstrated in vitro that EGFR L718V mutation mediates resistance to osimertinib, but retains sensitivity to afatinib. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 35-39 29571987-10 2018 Furthermore, combinatorial treatment of first/third-generation EGFR-TKI and crizotinib was efficaciously administrated into two patients with newly acquired MET amplification after osimertinib resistance. osimertinib 181-192 epidermal growth factor receptor Homo sapiens 63-67 29571987-13 2018 Moreover, we reported the first clinical evidence of efficacy generated by combination of first-generation EGFR-TKI icotinib and crizotinib after the resistance to osimertinib. osimertinib 164-175 epidermal growth factor receptor Homo sapiens 107-111 29496249-0 2018 High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 23-27 29496249-1 2018 OBJECTIVES: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that can overcome resistance due to the Thr790Met (T790M) mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-78 29496249-1 2018 OBJECTIVES: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that can overcome resistance due to the Thr790Met (T790M) mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 29496249-3 2018 We investigated the correlation between the ratio of T790M to EGFR activating mutation and the response to osimertinib. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 62-66 29496249-6 2018 We calculated the ratio of T790M to EGFR activating mutations and correlated it with the systemic response to osimertinib. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 36-40 29496249-13 2018 CONCLUSION: The T790M ratio to EGFR activating mutation in tumor may correlate with the response to osimertinib, and patients with a higher T790M ratio have a longer treatment history. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 31-35 29242281-0 2018 FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 112-144 29242281-1 2018 On March 30, 2017, the U.S. Food and Drug Administration (FDA) approved osimertinib for the treatment of patients with metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive, non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed following EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 131-163 29242281-1 2018 On March 30, 2017, the U.S. Food and Drug Administration (FDA) approved osimertinib for the treatment of patients with metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive, non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed following EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 165-169 29242281-1 2018 On March 30, 2017, the U.S. Food and Drug Administration (FDA) approved osimertinib for the treatment of patients with metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive, non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed following EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 308-312 29242281-6 2018 The toxicity profile of osimertinib compared favorably with the profile of other approved EGFR TKIs and chemotherapy. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 90-94 29242281-8 2018 Herein, we review the benefit-risk assessment of osimertinib that led to regular approval, for patients with metastatic NSCLC harboring EGFR TKI whose disease has progressed on or after EGFR TKI therapy. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 136-140 29242281-8 2018 Herein, we review the benefit-risk assessment of osimertinib that led to regular approval, for patients with metastatic NSCLC harboring EGFR TKI whose disease has progressed on or after EGFR TKI therapy. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 186-190 29242281-9 2018 IMPLICATIONS FOR PRACTICE: Osimertinib administered to metastatic non-small cell lung cancer (NSCLC) patients harboring an EGFR T790M mutation, who have progressed on or following EGFR TKI therapy, demonstrated a substantial improvement over platinum-based doublet chemotherapy as well as durable intracranial responses. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 123-127 29242281-9 2018 IMPLICATIONS FOR PRACTICE: Osimertinib administered to metastatic non-small cell lung cancer (NSCLC) patients harboring an EGFR T790M mutation, who have progressed on or following EGFR TKI therapy, demonstrated a substantial improvement over platinum-based doublet chemotherapy as well as durable intracranial responses. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 180-184 29455650-11 2018 Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 97-101 29455654-3 2018 Osimertinib is one of the third generation EGFR TKIs and is currently the most advanced in clinical development. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 43-47 29455654-6 2018 Osimertinib under FLAURA study had been shown to have better progression-free survival over first generation EGFR TKI in the first line setting and likely will become the new standard of care. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 109-113 29128427-0 2018 Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 57-61 29849216-0 2018 Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer? osimertinib 7-18 epidermal growth factor receptor Homo sapiens 76-108 29467275-6 2018 Additionally, naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 110-114 29423594-3 2018 Various third-generation EGFR TKIs have been developed to specifically target this acquired mutation, of which osimertinib is currently the only approved agent. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 25-29 29423594-6 2018 However, as patients invariably develop resistance during treatment with osimertinib, most commonly with the development of triple mutated EGFR (sensitizing mutations/T790M/C797S), which is resistant to all existing EGFR TKIs, efforts are currently ongoing to develop new strategies or novel compounds to specifically target this resistance mechanism. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 139-143 29423594-6 2018 However, as patients invariably develop resistance during treatment with osimertinib, most commonly with the development of triple mutated EGFR (sensitizing mutations/T790M/C797S), which is resistant to all existing EGFR TKIs, efforts are currently ongoing to develop new strategies or novel compounds to specifically target this resistance mechanism. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 216-220 29411527-1 2018 Osimertinib is a novel, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 55-87 29411527-1 2018 Osimertinib is a novel, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 89-93 29411527-1 2018 Osimertinib is a novel, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 131-135 29411527-1 2018 Osimertinib is a novel, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 131-135 29411527-2 2018 Here, we report a woman with EGFR-mutated lung adenocarcinoma who, after 23-month treatment with gefitinib, developed the EGFR T790M mutation, which converted the T790M status from positive to negative before osimertinib treatment and developed MET amplification, leading to rapid progression on osimertinib in two months. osimertinib 209-220 epidermal growth factor receptor Homo sapiens 29-33 29411527-2 2018 Here, we report a woman with EGFR-mutated lung adenocarcinoma who, after 23-month treatment with gefitinib, developed the EGFR T790M mutation, which converted the T790M status from positive to negative before osimertinib treatment and developed MET amplification, leading to rapid progression on osimertinib in two months. osimertinib 209-220 epidermal growth factor receptor Homo sapiens 122-126 29411527-2 2018 Here, we report a woman with EGFR-mutated lung adenocarcinoma who, after 23-month treatment with gefitinib, developed the EGFR T790M mutation, which converted the T790M status from positive to negative before osimertinib treatment and developed MET amplification, leading to rapid progression on osimertinib in two months. osimertinib 296-307 epidermal growth factor receptor Homo sapiens 29-33 29411527-2 2018 Here, we report a woman with EGFR-mutated lung adenocarcinoma who, after 23-month treatment with gefitinib, developed the EGFR T790M mutation, which converted the T790M status from positive to negative before osimertinib treatment and developed MET amplification, leading to rapid progression on osimertinib in two months. osimertinib 296-307 epidermal growth factor receptor Homo sapiens 122-126 29782558-0 2018 Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 25-57 29782558-0 2018 Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 59-63 29782562-0 2018 First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 67-71 29590540-0 2018 Osimertinib in EGFR Mutation-Positive Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 29595922-0 2018 Osimertinib in EGFR Mutation-Positive Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 29595923-0 2018 Osimertinib in EGFR Mutation-Positive Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 29595924-0 2018 Osimertinib in EGFR Mutation-Positive Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 28841389-0 2018 Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 39-43 28841389-1 2018 Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naive patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). osimertinib 161-172 epidermal growth factor receptor Homo sapiens 177-209 29713646-14 2018 Conclusions: EGFR C797S/G mutation and the same one presented on the same allele with EGFR T790M mutation were the most common mutation feature and played a key role in resistance to osimertinib in Chinese patients with NSCLC. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 13-17 29713646-14 2018 Conclusions: EGFR C797S/G mutation and the same one presented on the same allele with EGFR T790M mutation were the most common mutation feature and played a key role in resistance to osimertinib in Chinese patients with NSCLC. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 86-90 29413968-5 2018 In this perspective, we report on a patient who developed a grade III QT prolongation during osimertinib (a third-generation epidermal growth factor receptor [EGFR]-TKI) treatment. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 125-157 29413968-5 2018 In this perspective, we report on a patient who developed a grade III QT prolongation during osimertinib (a third-generation epidermal growth factor receptor [EGFR]-TKI) treatment. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 159-163 29239002-1 2018 Osimertinib is an oral, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 159-163 29610752-0 2018 First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 40-44 29732058-0 2018 L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 13-17 29732058-4 2018 Here, we investigated the inhibitory process for EGFR T790M (susceptible to osimertinib) and EGFR T790M/L718Q (resistant to osimertinib), by modelling the chemical step (i.e., alkylation of Cys797) using QM/MM simulations and the recognition step by MD simulations coupled with free-energy calculations. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 49-53 29732058-6 2018 The results show that Gln718 affects the conformational space of the EGFR-osimertinib complex, stabilizing a conformation of acrylamide which prevents reaction with Cys797. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 69-73 29101057-0 2018 Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 38-42 29212784-3 2018 Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M-EGFR, but several mechanisms, including a third-site mutation, C797S, confer renewed resistance. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 66-70 28880737-0 2018 Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 57-61 28880737-1 2018 AIM: This study presents the cost-utility analysis that was developed to inform the NICE health technology assessment of osimertinib vs platinum-based doublet chemotherapy (PDC) in patients with EGFR-T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 195-199 28880737-1 2018 AIM: This study presents the cost-utility analysis that was developed to inform the NICE health technology assessment of osimertinib vs platinum-based doublet chemotherapy (PDC) in patients with EGFR-T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 342-346 28880737-12 2018 CONCLUSIONS: Osimertinib may be considered a cost-effective treatment option compared with PDC in the second-line setting in patients with EGFR-T790M mutation-positive NSCLC from a UK payer perspective. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 139-143 29101057-0 2018 Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 127-131 29101057-1 2018 OBJECTIVE: The aim of this study was to investigate the cost-effectiveness of osimertinib for the treatment of advanced NSCLC with an EGFR T790M mutation after the failure of first-line EGFR tyrosine kinase inhibitor (TKI) therapy. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 134-138 29249325-1 2018 BACKGROUND: Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 112-116 29249325-1 2018 BACKGROUND: Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 157-189 29249325-1 2018 BACKGROUND: Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 191-195 29249325-2 2018 We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 73-77 29399354-0 2018 Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 79-112 29399354-1 2018 Osimertinib, a third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated to be effective for treating patients with T790M-positive advanced non-small cell lung cancer (NSCLC) with a relatively good performance status (grade 0-1). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 32-65 29399354-1 2018 Osimertinib, a third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated to be effective for treating patients with T790M-positive advanced non-small cell lung cancer (NSCLC) with a relatively good performance status (grade 0-1). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 67-71 29383041-1 2018 Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management of EGFR mutation-positive non-small-cell lung cancer (NSCLC), with others in development. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 5-37 29383041-1 2018 Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management of EGFR mutation-positive non-small-cell lung cancer (NSCLC), with others in development. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 39-43 29383041-1 2018 Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management of EGFR mutation-positive non-small-cell lung cancer (NSCLC), with others in development. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 174-178 29383041-3 2018 Furthermore, emerging data indicate that first- (erlotinib and gefitinib), second- (afatinib) and third-generation (osimertinib) EGFR TKIs differ in terms of efficacy and tolerability profiles. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 129-133 29403309-1 2018 Background: The AURA3 clinical trial has shown that advanced non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations in circulating tumor DNA (ctDNA) could benefit from osimertinib. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 110-114 29151359-0 2018 Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 25-29 29151359-1 2018 BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 127-131 29151359-1 2018 BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 168-172 29151359-1 2018 BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 168-172 29151359-2 2018 We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 87-91 29151359-11 2018 CONCLUSIONS: Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 111-115 29320658-0 2018 Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 39-43 30144837-4 2018 Currently, for patients with advanced adenocarcinomas, testing for sensitizing mutations in epidermal growth factor receptor (EGFR) is mandatory prior to the administration of anti-EGFR inhibitors such as erlotinib, gefitinib, afatinib, or osimertinib. osimertinib 240-251 epidermal growth factor receptor Homo sapiens 92-124 30144837-4 2018 Currently, for patients with advanced adenocarcinomas, testing for sensitizing mutations in epidermal growth factor receptor (EGFR) is mandatory prior to the administration of anti-EGFR inhibitors such as erlotinib, gefitinib, afatinib, or osimertinib. osimertinib 240-251 epidermal growth factor receptor Homo sapiens 126-130 29462255-0 2018 Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 51-55 29331646-6 2018 For oncogene-addicted NSCLC, next-generation tyrosine kinase inhibitors (TKIs) (such as osimertinib or alectinib) have demonstrated increased response rates and progression-free survival compared with first-generation TKIs in patients with both EGFR-mutated and ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 245-249 29462255-1 2018 Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 43-75 29462255-1 2018 Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 77-81 29462255-1 2018 Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 162-166 29462255-1 2018 Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 162-166 29190637-0 2018 Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 85-89 28730963-1 2018 BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 76-108 28730963-1 2018 BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 110-114 28730963-1 2018 BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. osimertinib 25-28 epidermal growth factor receptor Homo sapiens 76-108 28730963-1 2018 BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. osimertinib 25-28 epidermal growth factor receptor Homo sapiens 110-114 29101057-2 2018 METHODS: A mathematical model was established by combining a decision tree and the Markov approach to project the cost-effectiveness of osimertinib versus standard chemotherapy for the treatment of patients who harbor an EGFR T790M mutation and have disease progression after first-line EGFR TKI therapy with or without metastases to the central nervous system. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 221-225 29101057-2 2018 METHODS: A mathematical model was established by combining a decision tree and the Markov approach to project the cost-effectiveness of osimertinib versus standard chemotherapy for the treatment of patients who harbor an EGFR T790M mutation and have disease progression after first-line EGFR TKI therapy with or without metastases to the central nervous system. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 287-291 29190637-9 2018 CONCLUSIONS: Osimertinib 80 mg is a useful therapeutic option for refractory LM after classical EGFR-TKI failure. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 96-100 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 65-97 28989039-0 2018 First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 76-80 30957057-0 2018 Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 80-84 29290257-1 2018 OBJECTIVES: EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. osimertinib 241-252 epidermal growth factor receptor Homo sapiens 12-16 29290257-1 2018 OBJECTIVES: EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. osimertinib 241-252 epidermal growth factor receptor Homo sapiens 103-107 29290257-1 2018 OBJECTIVES: EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. osimertinib 241-252 epidermal growth factor receptor Homo sapiens 103-107 29290257-9 2018 For three patients, EGFR mutational analysis was T790M-negative when re-assessed by using a less sensitive method (therascreen ) on the same liquid biopsy sample analysed by ddPCR before osimertinib therapy. osimertinib 187-198 epidermal growth factor receptor Homo sapiens 20-24 30069773-7 2018 On this basis, osimertinib has proven more efficacious than platinum-based chemotherapy in the setting of EGFR T790M-positive NSCLCs pretreated with a first- or second-generation EGFR-TKI. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 106-110 30069773-7 2018 On this basis, osimertinib has proven more efficacious than platinum-based chemotherapy in the setting of EGFR T790M-positive NSCLCs pretreated with a first- or second-generation EGFR-TKI. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 179-183 30069773-8 2018 More recently, in another phase 3 trial, osimertinib outperformed gefitinib or erlotinib as first-line treatment of EGFR-mutated (ex19del or L858R) advanced NSCLCs, thus emerging as a new standard of care in this setting. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 116-120 29217691-1 2018 Osimertinib is more effective as first-line therapy than other EGFR inhibitors for patients with advanced EGFR-mutated non-small cell lung cancer-notably Asians, who have a higher incidence of the disease compared with Western populations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 106-110 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 99-103 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 163-167 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 163-167 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 163-167 30631243-2 2018 Relative to standard of care first-generation EGFR TKIs (erlotinib or gefitinib) as first-line treatment of EGFR activating mutation-positive advanced NSCLC, osimertinib significantly prolongs median progression-free survival (PFS), with separation of the Kaplan-Meier PFS survival curves evident by the first assessment timepoint of 6 weeks. osimertinib 158-169 epidermal growth factor receptor Homo sapiens 108-112 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 99-103 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 163-167 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 163-167 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 163-167 30631243-1 2018 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 65-97 28526474-2 2017 Third-generation EGFR TKIs against the T790M mutation have been in active clinical development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 17-21 28754471-3 2017 Being implicated in the development of a number of the most lethal cancers worldwide, EGFR has long been considered as a focal target for cancer therapies, ever since the FDA approval of "Gefitinib" in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor "Osimertinib" in 2015. osimertinib 277-288 epidermal growth factor receptor Homo sapiens 86-90 29160717-4 2017 Although the recently approved osimertinib is effective for the EGFRT790M-positive NSCLC, the osimertinib-resistant EGFR mutation is rapidly developed, too. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 64-68 29202823-0 2017 Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 78-82 29354805-4 2017 Particularly, a newer generation of EGFR-TKIs, including osimertinib and AZD3759, has been developed. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 36-40 29255376-0 2017 Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 27-31 29255376-2 2017 The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 21-25 29255376-2 2017 The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 61-65 29255376-3 2017 Mechanisms of acquired resistance are emerging, and here we describe a cis-oriented solvent-front EGFR G796S mutation as the resistance mechanism observed in a progression biopsy and circulating tumor DNA (ctDNA) from a patient with initial response followed by progression on osimertinib. osimertinib 277-288 epidermal growth factor receptor Homo sapiens 98-102 29255376-4 2017 This is one of the earliest reports of a sole solvent-front tertiary EGFR mutation as a resistance mechanism to osimertinib. osimertinib 112-123 epidermal growth factor receptor Homo sapiens 69-73 29255376-7 2017 We observe that nearly all clinical osimertinib-resistant tertiary EGFR mutations are oriented in cis with EGFR T790M. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 67-71 29255376-7 2017 We observe that nearly all clinical osimertinib-resistant tertiary EGFR mutations are oriented in cis with EGFR T790M. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 107-111 29202823-9 2017 CONCLUSIONS: Our data suggest that concomitant treatment with osimertinib and T-DM1 may be a promising therapeutic strategy for EGFR-mutant NSCLC. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 128-132 29202823-0 2017 Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 108-112 29202823-1 2017 BACKGROUND: Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-50 29125233-5 2017 In vitro, H1975 cells were sensitive to the third-generation epidermal growth factor receptor inhibitor osimertinib. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 61-93 28843359-0 2017 Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 57-61 29285266-0 2017 Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 110-142 29285266-2 2017 Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 17-21 29285266-2 2017 Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 100-104 29285266-8 2017 For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 12-16 29285266-11 2017 On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. osimertinib 17-28 epidermal growth factor receptor Homo sapiens 90-94 29095090-6 2017 Expert opinion: Osimertinib is the standard-of-care for EGFR-mutated patients progressing to first-line EGFR-TKIs due to the acquired EGFR T790M mutation. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 56-60 29095090-6 2017 Expert opinion: Osimertinib is the standard-of-care for EGFR-mutated patients progressing to first-line EGFR-TKIs due to the acquired EGFR T790M mutation. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 104-108 29095090-6 2017 Expert opinion: Osimertinib is the standard-of-care for EGFR-mutated patients progressing to first-line EGFR-TKIs due to the acquired EGFR T790M mutation. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 104-108 29095090-7 2017 Results from the head-to-head first-line trial comparing osimertinib versus gefitinib or erlotinib in activating EGFR mutations might change the front-line approach. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 113-117 29096978-0 2017 Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 76-80 29173769-0 2017 Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 35-39 29173769-5 2017 Recent phase one data and our case indicate osimertinib should be viewed as a best practice for treatment of LM disease in epidermal growth factor receptor (EGFR) mutated NSCLC regardless of T790M status. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 123-155 29173769-5 2017 Recent phase one data and our case indicate osimertinib should be viewed as a best practice for treatment of LM disease in epidermal growth factor receptor (EGFR) mutated NSCLC regardless of T790M status. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 157-161 29299405-5 2017 New agents targeting the T790M mutation have undergone clinical development, and among these, osimertinib has shown significant activity in relapsing EGFR mutation positive patients harbouring the T790M mutation. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 150-154 29299414-0 2017 Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 39-43 28880013-9 2017 The results demonstrate that osimertinib reduces PD-L1 mRNA expression and induces its protein degradation, suggesting that osimertinib may reactivate the immune activity of T cells in the tumor microenvironment in EGFR-mutated NSCLC patients. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 215-219 28880013-9 2017 The results demonstrate that osimertinib reduces PD-L1 mRNA expression and induces its protein degradation, suggesting that osimertinib may reactivate the immune activity of T cells in the tumor microenvironment in EGFR-mutated NSCLC patients. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 215-219 28765329-1 2017 Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 126-130 28765329-1 2017 Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 145-149 28765329-1 2017 Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. osimertinib 86-94 epidermal growth factor receptor Homo sapiens 145-149 28662863-1 2017 INTRODUCTION: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 111-115 28662863-5 2017 RESULTS: At the development of resistance to osimertinib, the patient"s plasma sample revealed EGFR C797S located in trans with T790M. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 95-99 29074213-0 2017 Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 62-66 28830985-0 2017 Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 75-79 28880013-0 2017 Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 61-65 28880013-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-76 28880013-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 78-82 28880013-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 160-164 28880013-3 2017 Here, we showed that osimertinib decreased PD-L1 expression in human EGFR mutant NSCLC cells in vitro. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 69-73 28806116-12 2017 In patients with a sensitizing EGFR mutation, disease progression after first-line epidermal growth factor receptor tyrosine kinase inhibitor therapy, and T790M mutation, osimertinib is recommended; if NSCLC lacks the T790M mutation, then chemotherapy is recommended. osimertinib 171-182 epidermal growth factor receptor Homo sapiens 31-35 28843359-1 2017 INTRODUCTION: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor has demonstrated efficacy in tumors harboring the EGFR T790M resistance mutation. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 46-50 28843359-1 2017 INTRODUCTION: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor has demonstrated efficacy in tumors harboring the EGFR T790M resistance mutation. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 127-131 28961841-0 2017 Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). osimertinib 64-75 epidermal growth factor receptor Homo sapiens 13-17 28961841-1 2017 Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 90-94 28961841-1 2017 Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 210-214 28751247-1 2017 INTRODUCTION: Osimertinib is an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR TKI and T790M resistance mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 59-63 28751247-1 2017 INTRODUCTION: Osimertinib is an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR TKI and T790M resistance mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 110-114 28751247-9 2017 Osimertinib modulated key EGFR signaling pathways and led to increased immune cell infiltration. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 26-30 28939151-0 2017 Osimertinib for Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-48 29404300-0 2017 Good response to erlotinib in a patient after progression on osimertinib: A rare case of spatiotemporal T790M heterogeneity in a patient with epidermal growth factor receptor-mutant nonsmall cell lung cancer. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 142-174 28884371-1 2017 The European Commision (EC) recently approved osimertinib for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR T790M mutations. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 175-179 29070999-10 2017 CONCLUSION: To our knowledge, this is the second reported case of LM in a patient with lung cancer harboring an EGFR T790M mutation that was successfully treated with osimertinib. osimertinib 167-178 epidermal growth factor receptor Homo sapiens 112-116 29100434-13 2017 These patients responded to the 3rd-generation EGFR-TKI osimertinib. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 47-51 29156777-7 2017 The analysis of cftDNA in 5 patients treated with osimertinib revealed a marked decrease of all EGFR mutant alleles. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 96-100 28716641-0 2017 Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 62-66 28716641-1 2017 Osimertinib has been identified as a promising therapeutic drug targeting for EGFR T790M mutant non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 78-82 28341106-0 2017 The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 105-109 28341106-2 2017 The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor (EGFR)-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non-small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 64-68 28701107-2 2017 The EGFR T790M secondary mutation that accounts for ~50% of resistance is now treatable with osimertinib. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 4-8 28794368-0 2017 Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 53-85 28794368-0 2017 Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 87-91 28838712-0 2017 T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 6-10 28838392-5 2017 The cobas EGFR Mutation Test (Roche Molecular Systems Inc., Branchburg, New Jersey, USA) is approved as a companion diagnostic for osimertinib, a third-generation EGFR-tyrosine kinase inhibitor approved in Japan. osimertinib 132-143 epidermal growth factor receptor Homo sapiens 11-15 28838392-5 2017 The cobas EGFR Mutation Test (Roche Molecular Systems Inc., Branchburg, New Jersey, USA) is approved as a companion diagnostic for osimertinib, a third-generation EGFR-tyrosine kinase inhibitor approved in Japan. osimertinib 132-143 epidermal growth factor receptor Homo sapiens 164-168 28838405-0 2017 Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 13-17 28838405-0 2017 Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 36-40 28838405-3 2017 The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment. osimertinib 248-259 epidermal growth factor receptor Homo sapiens 4-8 28838405-3 2017 The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment. osimertinib 248-259 epidermal growth factor receptor Homo sapiens 182-186 28808573-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-76 28808573-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 78-82 28808573-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 123-127 28528303-5 2017 We demonstrate that 7c is capable of recapitulating the signaling effects and antiproliferative activity of combined treatment with the approved ALK inhibitor ceritinib and T790M EGFR inhibitor osimertinib against patient-derived non-small cell lung cancer cell line, DFCI032 which harbors both EML4-ALK and activated EGFR. osimertinib 194-205 epidermal growth factor receptor Homo sapiens 179-183 28860885-5 2017 Osimertinib is a third-generation TKI designed to target both EGFR TKI-sensitizing mutations and T790M, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 62-66 28860885-5 2017 Osimertinib is a third-generation TKI designed to target both EGFR TKI-sensitizing mutations and T790M, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 128-132 28860885-6 2017 Based on its pronounced clinical activity and good safety profile demonstrated in early Phase I and II trials, osimertinib received first approval in 2015 by the US FDA and in early 2016 by European Medicines Agency for the treatment of EGFR T790M mutation-positive NSCLC patients in progression after EGFR TKI therapy. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 237-241 28860885-6 2017 Based on its pronounced clinical activity and good safety profile demonstrated in early Phase I and II trials, osimertinib received first approval in 2015 by the US FDA and in early 2016 by European Medicines Agency for the treatment of EGFR T790M mutation-positive NSCLC patients in progression after EGFR TKI therapy. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 302-306 28860885-7 2017 Recent results from the Phase III AURA3 trial demonstrated the superiority of osimertinib over standard platinum-based doublet chemotherapy for treatment of patients with advanced EGFR T790M mutation-positive NSCLC with disease progression following first-line EGFR TKI therapy, thus definitively establishing this third-generation TKI as the standard of care in this setting. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 180-184 28860885-7 2017 Recent results from the Phase III AURA3 trial demonstrated the superiority of osimertinib over standard platinum-based doublet chemotherapy for treatment of patients with advanced EGFR T790M mutation-positive NSCLC with disease progression following first-line EGFR TKI therapy, thus definitively establishing this third-generation TKI as the standard of care in this setting. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 261-265 28527899-0 2017 EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 0-4 28527899-1 2017 INTRODUCTION: Osimertinib is an oral, central nervous system-active, EGFR tyrosine kinase inhibitor (TKI) for the treatment of EGFR T790M-positive advanced NSCLC. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 69-73 28527899-1 2017 INTRODUCTION: Osimertinib is an oral, central nervous system-active, EGFR tyrosine kinase inhibitor (TKI) for the treatment of EGFR T790M-positive advanced NSCLC. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 127-131 28527899-2 2017 Here we have evaluated EGFR mutation frequencies in two phase II studies of osimertinib (AURA extension and AURA2). osimertinib 76-87 epidermal growth factor receptor Homo sapiens 23-27 28676222-4 2017 Third-generation EGFR-TKIs such as osimertinib have been developed with the aim of overcoming the effects of EGFR T790M resistance mutation, which occurs in half of the patients with disease progression on EGFR-TKI therapy. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 17-21 28676222-4 2017 Third-generation EGFR-TKIs such as osimertinib have been developed with the aim of overcoming the effects of EGFR T790M resistance mutation, which occurs in half of the patients with disease progression on EGFR-TKI therapy. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 109-113 28676222-4 2017 Third-generation EGFR-TKIs such as osimertinib have been developed with the aim of overcoming the effects of EGFR T790M resistance mutation, which occurs in half of the patients with disease progression on EGFR-TKI therapy. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 109-113 28676222-5 2017 Osimertinib has become the standard treatment in patients for whom tumor re-biopsy reveals an acquired EGFR T790M mutation following EGFR-TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 103-107 28676222-5 2017 Osimertinib has become the standard treatment in patients for whom tumor re-biopsy reveals an acquired EGFR T790M mutation following EGFR-TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 133-137 28778263-5 2017 This case also shows how resistance to third-generation EGFR-TKI osimertinib can be mediated by the development of phenotypic neuroendocrine transformation, which in the present case occurred during first-line treatment with erlotinib. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 56-60 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 65-97 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 99-103 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 150-154 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 150-154 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 65-97 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 99-103 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 150-154 28710746-1 2017 Osimertinib (Tagrisso ) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 150-154 28710746-3 2017 In the pivotal, international AURA3 trial in patients with T790M-positive advanced NSCLC who had disease progression after EGFR TKI therapy, osimertinib treatment significantly prolonged progression-free survival (PFS; primary endpoint) compared with platinum-pemetrexed therapy at the time of the primary analysis. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 123-127 28710746-8 2017 With limited treatment options available in this setting, osimertinib is an important option in adult patients with advanced EGFR T790M-positive NSCLC. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 125-129 28708233-8 2017 To date, the Cys797Ser (C797S) mutation in exon 20 of EGFR is the most well-known resistance mutation after osimertinib. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 54-58 28420725-2 2017 Circulating tumor DNA (ctDNA) is released into the circulation by tumor cell turnover and has been shown to be detectable in urine.Experimental Design: We tested the hypothesis that dynamic changes in EGFR activating (exon 19del and L858R) and resistance (T790M) mutation levels detected in urine could inform tumor response within days of therapy for advanced non-small cell lung cancer (NSCLC) patients receiving osimertinib, a second-line third-generation anti-EGFR tyrosine kinase inhibitor.Results: Eight of nine evaluable NSCLC patients had detectable T790M-mutant DNA fragments in pretreatment baseline samples. osimertinib 415-426 epidermal growth factor receptor Homo sapiens 201-205 28781309-0 2017 Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). osimertinib 32-43 epidermal growth factor receptor Homo sapiens 58-90 28781309-0 2017 Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). osimertinib 32-43 epidermal growth factor receptor Homo sapiens 92-96 28781309-2 2017 A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 119-151 28781309-2 2017 A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 153-157 29050315-0 2017 The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. osimertinib 170-181 epidermal growth factor receptor Homo sapiens 103-107 28699260-3 2017 Treatment with the third-generation EGFR TKI, osimertinib can prolong progression free survival in patients with the T790M mutation, so it is important to determine the resistance mechanism in order to plan ongoing therapeutic strategies. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 36-40 28794650-0 2017 Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 9-13 28794650-5 2017 Osimertinib is a third-generation EGFR-TKI designed for overcoming T790M-mediated resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 28794650-6 2017 Based on the results of efficacy and tolerability of Phase II and Phase III studies, osimertinib has been approved for treatment of advanced EGFRT790M+ mutation NSCLC following progression on a prior EGFR-TKI. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 141-145 28572531-5 2017 In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 132-136 28341106-4 2017 The primary objective is to evaluate the best strategy for sequencing of treatment with gefitinib and osimertinib in advanced NSCLC patients with common EGFR mutations, and to understand the value of liquid biopsy for the decision-making process. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 153-157 28274743-0 2017 Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 152-156 28419328-1 2017 Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the T790M mutation of EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-78 28572531-0 2017 EGFR G796D mutation mediates resistance to osimertinib. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 0-4 28572531-1 2017 Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 45-77 28572531-1 2017 Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 79-83 28572531-1 2017 Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 178-182 28572531-3 2017 Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 78-82 28577957-0 2017 EGFR T790M mutation testing within the osimertinib AURA Phase I study. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 0-4 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 21-53 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 55-59 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 137-141 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 137-141 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 137-141 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 137-141 28577957-10 2017 CONCLUSIONS: Within the osimertinib AURA Phase I study, EGFR mutation testing across three centralized laboratories using the cobas EGFR Mutation Test was feasible and successful, with strong concordance between local and central laboratory results, including for T790M. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 56-60 28577957-11 2017 The cobas EGFR Mutation Test has subsequently been approved as the companion diagnostic test for osimertinib in the USA and Japan. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 11-15 29404164-6 2017 Among those inhibitors, third-generation EGFR-TKIs such as osimertinib and rociletinib have gained prominence due to their high level of effectiveness and low toxicity profile. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 41-45 27986747-0 2017 Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 104-108 27986747-4 2017 Alternative splicing of BIM mRNA was analyzed by RT-PCR.Results:EGFR-mutated NSCLC cell lines with the BIM deletion polymorphism exhibited apoptosis resistance to osimertinib in a polymorphism dosage-dependent manner, and this resistance was overcome by combined use with vorinostat. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 64-68 27986747-7 2017 In xenograft models, combined use of vorinostat with osimertinib could regress tumors in EGFR-mutated NSCLC cells homozygous for the BIM deletion polymorphism. osimertinib 53-64 epidermal growth factor receptor Homo sapiens 89-93 27986747-8 2017 Moreover, this combination could induce apoptosis even when tumor cells acquired EGFR-T790M mutations.Conclusions: These findings indicate the importance of developing HDAC3-selective inhibitors, and their combined use with osimertinib, for treating EGFR-mutated lung cancers carrying the BIM deletion polymorphism. osimertinib 224-235 epidermal growth factor receptor Homo sapiens 250-254 28416483-0 2017 SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 102-106 28416483-1 2017 Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 17-21 28416483-1 2017 Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 116-120 28416483-4 2017 Here we report that Src family kinases (SFK) and focal adhesion kinase (FAK) sustain AKT and MAPK pathway signaling under continuous EGFR inhibition in osimertinib-sensitive cells. osimertinib 152-163 epidermal growth factor receptor Homo sapiens 133-137 28416483-7 2017 SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 62-66 28416483-7 2017 SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors. osimertinib 149-160 epidermal growth factor receptor Homo sapiens 62-66 28419328-1 2017 Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the T790M mutation of EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 28419328-1 2017 Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the T790M mutation of EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 153-157 28419328-7 2017 Among the six patients pretreated with a third-generation EGFR TKI, two (33%) responded to osimertinib. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 58-62 28419328-13 2017 Some patients pretreated with another third-generation EGFR TKI also responded to osimertinib. osimertinib 82-93 epidermal growth factor receptor Homo sapiens 55-59 28167215-4 2017 Fortunately, T790M secondary mutation, the main resistance mechanism, can be overcome by newly developed third-generation EGFR TKIs, such as osimertinib, while most combination trials trying to overcome resistance mechanisms other than T790M mutation have failed so far. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 122-126 28625641-0 2017 Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. osimertinib 192-203 epidermal growth factor receptor Homo sapiens 41-45 28625641-0 2017 Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. osimertinib 192-203 epidermal growth factor receptor Homo sapiens 141-145 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 9-41 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 43-47 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 111-115 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 111-115 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 9-41 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 43-47 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 111-115 28625641-1 2017 Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 111-115 28625641-2 2017 Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care. osimertinib 208-219 epidermal growth factor receptor Homo sapiens 38-42 28625641-7 2017 In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 88-92 28625641-7 2017 In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring. osimertinib 248-259 epidermal growth factor receptor Homo sapiens 88-92 28625641-8 2017 Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge. osimertinib 158-169 epidermal growth factor receptor Homo sapiens 78-82 28625643-0 2017 Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. osimertinib 147-158 epidermal growth factor receptor Homo sapiens 92-96 28625643-1 2017 Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 18-22 28625643-1 2017 Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 135-139 28625643-7 2017 Plasma levels of the activating EGFR-exon19del accurately paralleled the clinical and radiological progression of disease and allowed early detection of AR to osimertinib. osimertinib 159-170 epidermal growth factor receptor Homo sapiens 32-36 28625643-8 2017 Resistance to osimertinib coincided with the emergence of a small tumor cell subpopulation carrying the known EGFR-C797S resistance mutation and an additional subpopulation carrying amplified copies of EGFR-exon19del. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 110-114 28625643-8 2017 Resistance to osimertinib coincided with the emergence of a small tumor cell subpopulation carrying the known EGFR-C797S resistance mutation and an additional subpopulation carrying amplified copies of EGFR-exon19del. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 202-206 28625643-9 2017 Given the existence of multiple AR mechanisms, quantification of the original EGFR activation mutation, instead of the resistance mutations, can be efficiently used to monitor response to osimertinib, allowing early detection of AR. osimertinib 188-199 epidermal growth factor receptor Homo sapiens 78-82 28625643-11 2017 Selective amplification of the EGFR-exon19del allele may represent a novel resistance mechanism to osimertinib. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 31-35 28625644-6 2017 The next generation EGFR TKIs osimertinib and AZD3759 have improved BBB penetration and the BLOOM study of osimertinib and AZD3759 has reported highly promising intracranial efficacy and may herald a new frontier to treat this therapeutically challenging subset of advanced EGFR mutant patients. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 20-24 28607578-0 2017 Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 38-70 28607578-6 2017 The aim of this review is to discuss emerging data regarding the third-generation EGFR-TKI, osimertinib, for the treatment of EGFR T790M mutant advanced NSCLC. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 82-86 28607578-6 2017 The aim of this review is to discuss emerging data regarding the third-generation EGFR-TKI, osimertinib, for the treatment of EGFR T790M mutant advanced NSCLC. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 126-130 28093244-0 2017 Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. osimertinib 79-90 epidermal growth factor receptor Homo sapiens 19-23 28620581-4 2017 A number of third-generation TKIs are in clinical development, and osimertinib has been approved by the US Food and Drug Administration for the treatment of patients with EGFR T790M mutant lung cancer after failure of initial EGFR kinase therapy. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 171-175 28620581-4 2017 A number of third-generation TKIs are in clinical development, and osimertinib has been approved by the US Food and Drug Administration for the treatment of patients with EGFR T790M mutant lung cancer after failure of initial EGFR kinase therapy. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 226-230 28514610-0 2017 Osimertinib in EGFR T790M-Positive Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 28514611-0 2017 Osimertinib in EGFR T790M-Positive Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 30108799-0 2017 The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 105-109 28469919-0 2017 Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 54-58 28469919-3 2017 The T790M-resistant mutations are the most common, and osimertinib has been found to be effective in treating EGFR-T790M-positive patients. osimertinib 55-66 epidermal growth factor receptor Homo sapiens 110-114 27923840-0 2017 Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-48 27923840-1 2017 On November 13, 2015, the FDA granted accelerated approval to osimertinib (TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, with progression on or after EGFR tyrosine kinase inhibitor therapy. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 184-188 27923840-1 2017 On November 13, 2015, the FDA granted accelerated approval to osimertinib (TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, with progression on or after EGFR tyrosine kinase inhibitor therapy. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 307-311 28515244-5 2017 In patients with EGFR-mutant lung cancer, when resistance develops, physicians should seek to identify the T790M mutation using plasma and tissue assays, because osimertinib therapy is available for this mutation. osimertinib 162-173 epidermal growth factor receptor Homo sapiens 17-21 28221867-1 2017 Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. osimertinib 8-19 epidermal growth factor receptor Homo sapiens 39-71 28221867-1 2017 Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. osimertinib 8-19 epidermal growth factor receptor Homo sapiens 73-77 28221867-1 2017 Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. osimertinib 8-19 epidermal growth factor receptor Homo sapiens 130-134 28221867-15 2017 Conclusion In patients with EGFRm T790M advanced NSCLC who progress after EGFR-TKI treatment, osimertinib provides a high ORR, encouraging PFS, and durable response. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 28-32 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 64-96 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 98-102 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 228-232 28007627-9 2017 Three of four patients with ALK/EGFR co-alterations treated with an EGFR TKI achieved one or more responses in different lines of therapy: four patients had a partial response, three with afatinib and one with osimertinib. osimertinib 210-221 epidermal growth factor receptor Homo sapiens 32-36 28007627-9 2017 Three of four patients with ALK/EGFR co-alterations treated with an EGFR TKI achieved one or more responses in different lines of therapy: four patients had a partial response, three with afatinib and one with osimertinib. osimertinib 210-221 epidermal growth factor receptor Homo sapiens 68-72 28413660-0 2017 Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 122-154 28413660-1 2017 We herein report a case of dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor (EGFR) T790M mutation encoded in exon 20. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 149-181 28413660-1 2017 We herein report a case of dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor (EGFR) T790M mutation encoded in exon 20. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 183-187 28413660-4 2017 The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 61-65 28367058-0 2017 Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). osimertinib 105-116 epidermal growth factor receptor Homo sapiens 0-32 28367058-6 2017 Osimertinib is one of the third-generation EGFR TKIs with a high selective potency against T790M mutants. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 43-47 28367058-7 2017 In Phase I trial of osimertinib in advanced lung cancer after progression on EGFR TKIs, the response rate and disease control rate were 61% and 95%, respectively. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 77-81 28367058-9 2017 Osimertinib was approved by the US Food & Drug Administration in November 2015 for patients whose tumors exhibited T790M mutation and for those with progressive disease on other EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 182-186 28287083-0 2017 Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 30-34 28287083-0 2017 Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 80-84 28287083-1 2017 Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 50-82 28287083-1 2017 Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 84-88 28287083-1 2017 Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 155-159 28287083-1 2017 Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 155-159 28287083-2 2017 However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 112-116 28287083-2 2017 However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. osimertinib 156-167 epidermal growth factor receptor Homo sapiens 112-116 28848674-0 2017 Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 119-123 28848674-1 2017 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 73-105 28848674-1 2017 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 107-111 28848674-1 2017 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 248-252 28848674-3 2017 We now report the case of a patient aged 70 years with symptomatic LMC derived from NSCLC with the T790M mutation of EGFR who showed a clinical and radiographic response to osimertinib. osimertinib 173-184 epidermal growth factor receptor Homo sapiens 117-121 28517914-0 2017 Osimertinib in EGFR T790M-Positive Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 28416737-4 2017 Continuous EGFR inhibition of first-generation resistant tumors by sequential treatment with afatinib plus/minus cetuximab, followed by osimertinib, represented an effective therapeutic strategy in this model. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 11-15 28416737-7 2017 Cell lines established in vitro from gefitinib-, or afatinib- or osimertinib-resistant tumors showed metastatic properties and maintained EGFR-TKIs resistance in vitro, that was reverted by the combined blockade of Hh, with the selective SMO inhibitor sonidegib, and EGFR. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 138-142 28416737-7 2017 Cell lines established in vitro from gefitinib-, or afatinib- or osimertinib-resistant tumors showed metastatic properties and maintained EGFR-TKIs resistance in vitro, that was reverted by the combined blockade of Hh, with the selective SMO inhibitor sonidegib, and EGFR. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 267-271 28104619-0 2017 Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 23-27 28104619-3 2017 The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 174-178 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 64-96 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 98-102 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 228-232 28085680-9 2017 SUMMARY: Following progression with first-generation or second-generation EGFR TKIs, osimertinib was recently approved for the treatment of EGFR NSCLC. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 74-78 28085680-9 2017 SUMMARY: Following progression with first-generation or second-generation EGFR TKIs, osimertinib was recently approved for the treatment of EGFR NSCLC. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 140-144 28680534-3 2017 We found that acquired EGFR TKI resistance was associated with YAP over-expression (osimertinib-resistant cells) or YAP amplification (erlotinib- and gefitinib-resistant cells) along with EMT phenotypic changes. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 23-27 27923714-1 2017 INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 111-115 27923714-2 2017 Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. osimertinib 53-64 epidermal growth factor receptor Homo sapiens 103-107 28449447-0 2017 Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 62-66 28344665-5 2017 Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 27-31 28344665-5 2017 Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 189-193 28344665-5 2017 Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. osimertinib 260-271 epidermal growth factor receptor Homo sapiens 27-31 28344665-5 2017 Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. osimertinib 260-271 epidermal growth factor receptor Homo sapiens 189-193 28217439-5 2017 Third generation EGFR TKIs, such as Osimertinib, are focussing on resulting acquired TKI resistance. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 17-21 28138027-9 2017 Moreover, combined use of EGFR-TKI and crizotinib, a MET inhibitor, dramatically regressed leptomeningeal carcinomatosis with acquired resistance to gefitinib or osimertinib. osimertinib 162-173 epidermal growth factor receptor Homo sapiens 26-30 28089942-6 2017 Against this new target, different third-generation EGFR-mutant-selective TKIs, such as osimertinib, rociletinib and olmutinib, showed a great activity. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 52-56 27959700-0 2017 Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 38-42 27959700-1 2017 BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 90-94 27959700-1 2017 BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 127-131 27959700-10 2017 CONCLUSIONS: Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 253-257 27821604-0 2017 Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 41-45 27821604-2 2017 Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 96-100 27821604-2 2017 Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 201-205 27821604-2 2017 Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 96-100 28116908-2 2017 Osimertinib, a third-generation EGFR TKI, shows robust clinical efficacy in patients with T790 M-mutated lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 32-36 28116908-5 2017 Expert opinion: Osimertinib was recently licensed for use in NSCLC patients with acquired resistance to other EGFR TKIs due to a T790 M mutation. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 110-114 27599705-2 2017 The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) following treatment with nivolumab, an anti-Programmed Cell Death 1 (anti-PD1) antibody. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 61-65 27599705-2 2017 The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) following treatment with nivolumab, an anti-Programmed Cell Death 1 (anti-PD1) antibody. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 93-97 28213007-10 2017 HCC4006EDR cells, but not HCC4006ER cells, were highly sensitive to a third-generation EGFR-TKI, osimertinib. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 87-91 28178168-0 2017 Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 118-122 28178168-4 2017 Osimertinib is a third-generation oral, potent, and irreversible EGFR-TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 65-69 28178168-7 2017 PATIENT CONCERNS, DIAGNOSES, AND INTERVENTIONS: We experienced 2 NSCLC patients with the EGFR T790M mutation; a 67-year-old woman with symptomatic multiple brain metastases administered osimertinib as seventh-line chemotherapy, and a 76-year old man with an asymptomatic single brain metastasis administered osimertinib as fifth-line chemotherapy. osimertinib 186-197 epidermal growth factor receptor Homo sapiens 89-93 28178168-7 2017 PATIENT CONCERNS, DIAGNOSES, AND INTERVENTIONS: We experienced 2 NSCLC patients with the EGFR T790M mutation; a 67-year-old woman with symptomatic multiple brain metastases administered osimertinib as seventh-line chemotherapy, and a 76-year old man with an asymptomatic single brain metastasis administered osimertinib as fifth-line chemotherapy. osimertinib 308-319 epidermal growth factor receptor Homo sapiens 89-93 28449447-0 2017 Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 151-155 27840244-1 2017 The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M positive non-small cell lung cancer (NSCLC). osimertinib 64-75 epidermal growth factor receptor Homo sapiens 140-144 28149837-9 2016 Among the third-generation EGFR TKIs, osimertinib is today the only drug approved by the Food and Drug Administration and the European Medicines Agency to treat metastatic EGFR T790M NSCLC patients who have progressed on or after EGFR TKI therapy. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 27-31 28149837-9 2016 Among the third-generation EGFR TKIs, osimertinib is today the only drug approved by the Food and Drug Administration and the European Medicines Agency to treat metastatic EGFR T790M NSCLC patients who have progressed on or after EGFR TKI therapy. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 172-176 28149837-9 2016 Among the third-generation EGFR TKIs, osimertinib is today the only drug approved by the Food and Drug Administration and the European Medicines Agency to treat metastatic EGFR T790M NSCLC patients who have progressed on or after EGFR TKI therapy. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 172-176 29180936-0 2017 Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 59-63 29180936-0 2017 Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 95-99 29180936-6 2017 Osimertinib (Tagrisso ), a 3rd generation, irreversible EGFR tyrosine kinase inhibitor, constitutes a novel, highly efficacious treatment for NSCLC patients progressing on EGFR TKIs with T790M mutation confirmed as the resistance mechanism. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 56-60 29180936-6 2017 Osimertinib (Tagrisso ), a 3rd generation, irreversible EGFR tyrosine kinase inhibitor, constitutes a novel, highly efficacious treatment for NSCLC patients progressing on EGFR TKIs with T790M mutation confirmed as the resistance mechanism. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 172-176 29180936-6 2017 Osimertinib (Tagrisso ), a 3rd generation, irreversible EGFR tyrosine kinase inhibitor, constitutes a novel, highly efficacious treatment for NSCLC patients progressing on EGFR TKIs with T790M mutation confirmed as the resistance mechanism. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 56-60 29180936-6 2017 Osimertinib (Tagrisso ), a 3rd generation, irreversible EGFR tyrosine kinase inhibitor, constitutes a novel, highly efficacious treatment for NSCLC patients progressing on EGFR TKIs with T790M mutation confirmed as the resistance mechanism. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 172-176 29180936-9 2017 In this article, we present three cases that were successfully treated with osimertinib after progression on 1st and 2nd generation EGFR TKIs. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 132-136 27885838-0 2017 Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-20 27885838-2 2017 Osimertinib (AZD9291) has been developed as 3rd generation EGFR-TKI with activities against sensitizing mutations and T790 M resistance mutation, which account for about 50% of the mechanisms of acquired resistance to 1st or 2nd generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 59-63 27885838-2 2017 Osimertinib (AZD9291) has been developed as 3rd generation EGFR-TKI with activities against sensitizing mutations and T790 M resistance mutation, which account for about 50% of the mechanisms of acquired resistance to 1st or 2nd generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 240-244 27885838-3 2017 A recent phase I/II clinical trial with osimertinib for advanced NSCLC patients with known sensitizing EGFR mutations and documented disease progression on prior EGFR-TKIs revealed promising effect with acceptable toxicities. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 103-107 27885838-3 2017 A recent phase I/II clinical trial with osimertinib for advanced NSCLC patients with known sensitizing EGFR mutations and documented disease progression on prior EGFR-TKIs revealed promising effect with acceptable toxicities. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 162-166 27885838-6 2017 Expert commentary: The development of osimertinib has provided new therapeutic options for NSCLC patients harboring T790 M. Compared with other EGFR-TKIs including rociletinib, osimertinib seems to possess an advantage with respect to the effect and safety profile among existing EGFR-TKIs. osimertinib 177-188 epidermal growth factor receptor Homo sapiens 280-284 27821794-6 2017 Few options were available upon progression until the introduction of osimertinib, a kinase inhibitor that targets the T790M mutation, which was recently approved for use in patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who progressed on or after EGFR TKI therapy. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 199-203 27821794-6 2017 Few options were available upon progression until the introduction of osimertinib, a kinase inhibitor that targets the T790M mutation, which was recently approved for use in patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who progressed on or after EGFR TKI therapy. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 299-303 27861144-0 2016 Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 119-123 27861144-3 2016 Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that is potent and selective for sensitising (EGFRm) and T790M resistance mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 33-37 27861144-4 2016 Clinical studies have shown osimertinib to be efficacious in patients with EGFRm/ T790M advanced NSCLC who have progressed after EGFR-TKI treatment. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 75-79 27861144-7 2016 We show here that osimertinib suppresses glycolysis in parental EGFR-mutant lung adenocarcinoma lines, but has not in osimertinib-resistant cell lines. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 64-68 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 68-100 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 187-191 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 68-100 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 102-106 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 187-191 27770386-4 2016 AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positive advanced NSCLC patients. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 84-88 27618759-1 2016 INTRODUCTION: Osimertinib is an EGFR inhibitor licensed for the treatment of EGFR-mutant, T790M-positive NSCLC. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 32-36 27618759-1 2016 INTRODUCTION: Osimertinib is an EGFR inhibitor licensed for the treatment of EGFR-mutant, T790M-positive NSCLC. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 77-81 27751845-0 2016 Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 27751847-0 2016 Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 27-31 27751847-1 2016 BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 67-71 27751847-1 2016 BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 112-116 27751847-1 2016 BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 112-116 27751847-2 2016 We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed after previous therapy with an approved EGFR tyrosine-kinase inhibitor. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 68-72 27751847-18 2016 INTERPRETATION: Osimertinib showed clinical activity with manageable side-effects in patients with EGFR Thr790Met-positive NSCLC. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 99-103 27751847-19 2016 Therefore, osimertinib could be a suitable treatment for patients with EGFR Thr790Met-positive disease who have progressed on an EGFR tyrosine-kinase inhibitor. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 71-75 27751847-19 2016 Therefore, osimertinib could be a suitable treatment for patients with EGFR Thr790Met-positive disease who have progressed on an EGFR tyrosine-kinase inhibitor. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 129-133 27989430-0 2017 Osimertinib effective in EGFR T790M-positive lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 25-29 27784815-0 2016 Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 46-78 27784815-3 2016 Osimertinib is an oral, highly selective, irreversible inhibitor of both EGFR-activating mutations and the T790M-resistance mutation, while sparing the activity of wild-type EGFR This article reviews clinical trial development of osimertinib in patients with NSCLC, presenting efficacy and safety evidence for its value in the EGFR T790M mutation-positive population and in different settings, including patients with metastatic disease. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 73-77 28149764-1 2016 Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 90-94 28149764-1 2016 Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 157-161 28149764-1 2016 Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 157-161 27240419-8 2016 Our findings suggest that NSCLC harboring the EGFR L861Q mutation might be sensitive to afatinib or osimertinib and that NSCLC harboring the EGFR S768I mutation might be sensitive to afatinib. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 46-50 27694386-3 2016 Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib. osimertinib 240-251 epidermal growth factor receptor Homo sapiens 91-95 27694386-3 2016 Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib. osimertinib 240-251 epidermal growth factor receptor Homo sapiens 203-207 27469903-0 2016 Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. osimertinib 90-101 epidermal growth factor receptor Homo sapiens 75-79 27469903-1 2016 A method for the quantitative analysis by ultra-performance liquid chromatography-tandem mass spectrometry of the highly selective irreversible covalent inhibitor of EGFR-TK, osimertinib in human plasma was developed and validated, using pazopanib as an internal standard. osimertinib 175-186 epidermal growth factor receptor Homo sapiens 166-170 27649127-7 2016 Taken together, our findings suggest that osimertinib, a clinically-approved third-generation EGFR TKI, can reverse ABCB1-mediated MDR, which supports the combination therapy with osimertinib and ABCB1 substrates may potentially be a novel therapeutic stategy in ABCB1-positive drug resistant cancers. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 94-98 30643560-0 2016 AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC. osimertinib 18-26 epidermal growth factor receptor Homo sapiens 138-142 30643560-0 2016 AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 138-142 27435396-0 2016 Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 62-66 27435396-3 2016 EXPERIMENTAL DESIGN: We performed preclinical assessments of brain penetration and activity of osimertinib (AZD9291), an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M resistance mutations, and other EGFR-TKIs in various animal models of EGFR-mutant NSCLC brain metastases. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 148-152 27435396-3 2016 EXPERIMENTAL DESIGN: We performed preclinical assessments of brain penetration and activity of osimertinib (AZD9291), an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M resistance mutations, and other EGFR-TKIs in various animal models of EGFR-mutant NSCLC brain metastases. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 171-175 27435396-3 2016 EXPERIMENTAL DESIGN: We performed preclinical assessments of brain penetration and activity of osimertinib (AZD9291), an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M resistance mutations, and other EGFR-TKIs in various animal models of EGFR-mutant NSCLC brain metastases. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 171-175 27641462-2 2016 Osimertinib (AZD9291, Tagrisso ) is a third-generation, irreversible EGFR TKI, active in case of T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 69-73 27641462-3 2016 A large phase I trial showed the efficacy of osimertinib after failure of first-generation EGFR TKI (erlotinib, gefitinib), with response rate at 51% and up to 61% in case of T790M mutation. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 91-95 27910964-0 2016 Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 100-104 27910964-4 2016 Osimertinib is a third-generation EGFR TKI that was designed to overcome resistance from T790M mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 27649127-0 2016 Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 42-46 27649127-2 2016 In this study, we determine whether osimertinib, a novel selective, irreversible EGFR (epidermal growth factor receptor) TKI, could reverse ABC transporter-mediated MDR. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 81-85 27649127-2 2016 In this study, we determine whether osimertinib, a novel selective, irreversible EGFR (epidermal growth factor receptor) TKI, could reverse ABC transporter-mediated MDR. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 87-119 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 60-64 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 22-30 epidermal growth factor receptor Homo sapiens 60-64 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 22-30 epidermal growth factor receptor Homo sapiens 102-106 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 22-30 epidermal growth factor receptor Homo sapiens 102-106 27086175-0 2016 A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 8-12 27196753-4 2016 Furthermore, osimertinib stimulated the ATPase activity of both ABCB1 and ABCG2 and competed with the [(125)I] iodoarylazidoprazosin photolabeling bound to ABCB1 or ABCG2, but did not alter the localization and expression of ABCB1 or ABCG2 in mRNA and protein levels nor the phosphorylations of EGFR, AKT, and ERK. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 295-299 27177916-0 2016 Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naive Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 79-83 27177916-4 2016 Osimertinib (AZD9291) is a novel mono-anilino-pyrimidine third-generation EGFR TKI targeting both sensitizing and T790M EGFR-mutation which showed promising results in T790M-positive NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 74-78 27177916-4 2016 Osimertinib (AZD9291) is a novel mono-anilino-pyrimidine third-generation EGFR TKI targeting both sensitizing and T790M EGFR-mutation which showed promising results in T790M-positive NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 120-124 27226351-0 2016 Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 138-170 27448564-3 2016 AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 82-86 27448564-3 2016 AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. osimertinib 22-30 epidermal growth factor receptor Homo sapiens 82-86 27229180-3 2016 With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 78-82 27283993-5 2016 We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ~33% of patients after osimertinib treatment, occurs in <3% after rociletinib. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 20-24 27283993-5 2016 We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ~33% of patients after osimertinib treatment, occurs in <3% after rociletinib. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 54-58 27169328-4 2016 In this study, we investigated the interaction between ABCB1 and osimertinib, a novel selective, irreversible third-generation EGFR TKI that has recently been approved by the U.S. Food and Drug Administration. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 127-131 27169328-9 2016 Considering that osimertinib is a clinically approved third-generation EGFR TKI, our findings suggest that a combination therapy with osimertinib and conventional anticancer drugs may be beneficial to patients with MDR tumors. osimertinib 17-28 epidermal growth factor receptor Homo sapiens 71-75 27169328-9 2016 Considering that osimertinib is a clinically approved third-generation EGFR TKI, our findings suggest that a combination therapy with osimertinib and conventional anticancer drugs may be beneficial to patients with MDR tumors. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 71-75 26898616-5 2016 Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 55-59 27413714-4 2016 The main biological mechanism of resistance to approved first line EGFR inhibitors is the selection/acquisition of EGFR-T790M that in itself can be inhibited by osimertinib 80 mg/day, a 3(rd) generation EGFR inhibitor that is bypassed by EGFR-C797X mutations. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 67-71 27413714-4 2016 The main biological mechanism of resistance to approved first line EGFR inhibitors is the selection/acquisition of EGFR-T790M that in itself can be inhibited by osimertinib 80 mg/day, a 3(rd) generation EGFR inhibitor that is bypassed by EGFR-C797X mutations. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 115-119 27413714-4 2016 The main biological mechanism of resistance to approved first line EGFR inhibitors is the selection/acquisition of EGFR-T790M that in itself can be inhibited by osimertinib 80 mg/day, a 3(rd) generation EGFR inhibitor that is bypassed by EGFR-C797X mutations. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 115-119 27413714-4 2016 The main biological mechanism of resistance to approved first line EGFR inhibitors is the selection/acquisition of EGFR-T790M that in itself can be inhibited by osimertinib 80 mg/day, a 3(rd) generation EGFR inhibitor that is bypassed by EGFR-C797X mutations. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 115-119 27071706-6 2016 Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 76-80 26902828-1 2016 PURPOSE: Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 120-124 26902828-1 2016 PURPOSE: Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 189-193 27486808-0 2016 Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 61-93 26729184-1 2016 Osimertinib (Tagrisso( ), AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 124-128 26729184-1 2016 Osimertinib (Tagrisso( ), AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). osimertinib 13-21 epidermal growth factor receptor Homo sapiens 124-128 26729184-2 2016 Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-48 26729184-2 2016 Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 118-122 26729184-2 2016 Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 118-122 26729184-3 2016 In November 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 146-150 26729184-3 2016 In November 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 251-255 26729184-4 2016 Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-positive NSCLC in several countries. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 189-193 26943236-0 2016 The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 60-64 26943236-6 2016 We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 78-82 26943236-6 2016 We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 128-132 26950414-8 2016 EXPERT OPINION: It is important to note that there are other 3(rd) generation EGFR TKIs with activity against T790M already approved by the US FDA (osimertinib) and many others in development. osimertinib 148-159 epidermal growth factor receptor Homo sapiens 78-82 26959310-4 2016 On one hand, T790M second-site mutation has been recognized as a key mechanism of EGFR-TKI resistance, and third generation EGFR-TKIs such as osimertinib and rociletinib have been developed to overcome tumor cells harboring the T790M mutation. osimertinib 142-153 epidermal growth factor receptor Homo sapiens 82-86 26959310-4 2016 On one hand, T790M second-site mutation has been recognized as a key mechanism of EGFR-TKI resistance, and third generation EGFR-TKIs such as osimertinib and rociletinib have been developed to overcome tumor cells harboring the T790M mutation. osimertinib 142-153 epidermal growth factor receptor Homo sapiens 124-128 27491402-7 2016 CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 24-28 27486808-1 2016 BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 87-119 27486808-1 2016 BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 121-125 27486808-1 2016 BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 34-42 epidermal growth factor receptor Homo sapiens 87-119 27486808-1 2016 BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 34-42 epidermal growth factor receptor Homo sapiens 121-125 27486808-2 2016 CASE REPORT: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 126-130 26515464-9 2015 Interestingly, for EGFR exon 20 insertion mutations, most of which are known to be resistant to 1st and 2nd generation EGFR-TKIS, osimertinib was potent and presented a wide therapeutic window. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 19-23 26515464-9 2015 Interestingly, for EGFR exon 20 insertion mutations, most of which are known to be resistant to 1st and 2nd generation EGFR-TKIS, osimertinib was potent and presented a wide therapeutic window. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 119-123 26515464-10 2015 To our knowledge, this is the first report that has identified the therapeutic window of osimertinib for EGFR exon 20 insertion mutations. osimertinib 89-100 epidermal growth factor receptor Homo sapiens 105-109